WO2021031810A1

WO2021031810A1 - Application of ptbp1 inhibitor in preventing and/or treating nervous system disease related to functional neuronal death

Info

Publication number: WO2021031810A1
Application number: PCT/CN2020/105285
Authority: WO
Inventors: 杨辉; 周海波
Original assignee: 中国科学院脑科学与智能技术卓越创新中心
Priority date: 2019-08-16
Filing date: 2020-07-28
Publication date: 2021-02-25
Also published as: CN112451669A; WO2021031565A1

Abstract

The present invention relates to an application of a Ptbp1 inhibitor in preventing and/or treating a nervous system disease related to functional neuronal death. Specifically, the present invention provides a use of a Ptbp1 gene or RNA or encoded protein inhibitor thereof in preparing a composition or a preparation. The composition or the preparation is used for preventing and/or treating a nervous system disease related to functional neuronal death. By inhibiting the expression or activity of the Ptbp1 gene or RNA or encoded protein thereof in astrocytes in the brain, the transdifferentiation of the astrocytes into dopamine neurons can be effectively induced. In addition, by inhibiting the expression or activity of the Ptbp1 gene or RNA or encoded protein thereof in muller glial cells in the retina, the transdifferentiation of the muller glial cells into retinal ganglion cells can be effectively induced, thereby preventing and/or treating a nervous system disease related to functional neuronal death.

Description

Application of Ptbp1 inhibitors in the prevention and/or treatment of neurological diseases related to functional neuron death

Technical field

The invention relates to the field of biomedicine. More specifically, the present invention relates to the use of Ptbp1 inhibitors in the prevention and/or treatment of neurological diseases related to functional neuronal death.

Background technique

Parkinson's disease (PD) is a serious neurodegenerative disease characterized by the loss of dopamine neurons in the substantia nigra of the midbrain. Previous studies have achieved the direct reprogramming of astrocytes into dopamine neurons in vitro and in animal models by simultaneously overexpressing several transcription factors. However, so far, Ptbp1 mediated neuronal reprogramming in vivo has not been reported yet.

At present, the main treatment for Parkinson's disease is drugs represented by levodopa preparations. At the same time, surgical treatment can also improve symptoms to a certain extent. It should be pointed out that all these methods can only partially alleviate the disease, but cannot achieve the effect of preventing the development of the disease.

Therefore, there is an urgent need in the art to develop targets that can effectively treat neurodegenerative diseases.

Summary of the invention

The purpose of the present invention is to provide a target that can effectively treat neurodegenerative diseases.

Another purpose of the present invention is to provide a new target Ptbp1 for the treatment of Parkinson's disease. By inhibiting the expression of Ptbp1, astrocytes in the striatum can be directly converted into dopamine neurons and the phenotype of Parkinson's disease can be restored. .

Another objective of the present invention is to provide a new target Ptbp1 for the treatment of visual impairment. By inhibiting the expression of Ptbp1, the Muller glial cells in the retina can be directly transformed into optic ganglion cells and the phenotype of permanent visual impairment can be alleviated. .

In the first aspect of the present invention, there is provided a use of an inhibitor of Ptbp1 gene or RNA or its encoded protein for the preparation of a composition or preparation for the treatment of functional neuronal death-related nerves System diseases.

In another preferred embodiment, the composition or preparation is also used for one or more purposes selected from the following group:

(a1) Inducing astrocytes to transdifferentiate into dopamine neurons;

(b1) Treatment of dyskinesia in mammalian Parkinson's disease;

(c1) Inducing the transformation or differentiation of glial cells into functional neurons;

(d1) Treatment of neurological diseases related to optic ganglion cell (RGC) degeneration;

(e1) Prevention or treatment of retinal diseases;

(f1) Prevention and/or treatment of neurodegenerative diseases;

(g1) Transdifferentiation of Muller glial cells into optic ganglion cells;

(h1) Treatment of visual impairment caused by the death of mammalian optic ganglia.

In another preferred embodiment, the neurological disease is selected from the group consisting of glaucoma, age-related RGC loss, optic nerve damage, retinal ischemia, Leber hereditary optic neuropathy, Alzheimer's disease, Huntington's disease, mental Schizophrenia, depression, drug use, movement disorders (such as chorea, hypercholesterolemia and movement disorders), motor neuron injury diseases (such as amyotrophic lateral sclerosis, spinal cord injury), bipolar disorder, autism spectrum disorder (ASD), dysfunction, Parkinson's disease, or a combination thereof.

In another preferred embodiment, the glial cells are selected from the group consisting of astrocytes, MG cells, oligodendrocytes, ependymal cells, Schwan cells, NG2 cells, satellite cells, or combinations thereof.

In another preferred embodiment, the functional neuron is selected from the following group: RGC neuron, dopamine neuron, or a combination thereof.

In another preferred embodiment, the functional neurons are derived from the striatum.

In another preferred embodiment, the functional neurons are derived from mature retina.

In another preferred example, the retinal disease is a retinal disease caused by neurodegeneration.

In another preferred embodiment, the composition or preparation can treat retinal diseases caused by neurodegeneration by inducing MG cells to transdifferentiate into RGC cells.

In another preferred embodiment, the MG cells are Müller glial cells (Muller glial cells).

In another preferred embodiment, the MG cells are derived from the retina.

In another preferred example, the RGC cells are retinal ganglion cells.

In another preferred example, the RGC cells are functional RGCs.

In another preferred example, the RGC cells can be integrated into the visual pathway and improve visual function.

In another preferred example, the RGC cells can realize functional projection to the central visual area and improve visual function.

In another preferred example, the improvement of visual function is to improve the visual function of mammals suffering from retinal diseases caused by neurodegeneration.

In another preferred embodiment, the MG cells are transdifferentiated into RGC cells while also being differentiated into axonal cells.

In another preferred example, RGC (1) expresses Brn3a, Rbpms, Foxp2, Brn3c and/or paralbumin; (2) is F-RGC, type 3 RGC or PV-RGC; (3) is integrated in the Existing retinal pathways in the subject (for example, the central information can be projected to dLGN, and the vision can be partially restored by relaying the visual information to V1); and/or (4) the visual information can be received. It is characterized by the ability to establish action potentials in light stimulation, synaptic connections (for example with existing functional dLGN neurons in the brain), pre-synaptic neurotransmitter biogenesis and/or subsequent action.

In another preferred example, the Muller glial cells in the mature retina are reprogrammed and converted into RGC.

In another preferred example, dopamine neurons (1) express tyrosine hydroxylase (TH), dopamine transporter (DAT), vesicular monoamine transporter 2 (VMAT2), hybrid homology box 1 (Enl) , FoxA2 and/or LIM homeobox transcription factor 1 alpha (Lmxla); (2) exhibiting the biogenesis of presynaptic neurotransmitters; (3) being integrated into the existing nerves in the subject’s brain And/or (4) is characterized by its ability to establish action potentials, synaptic connections, pre-synaptic neurotransmitter biogenesis and/or post-synaptic reactions.

In another preferred example, multiple glial cells in the striatum are reprogrammed, and at least 10% or at least 30% of the glial cells are converted into dopamine neurons.

In another preferred example, the mammal includes a mammal suffering from a neurodegenerative disease.

In another preferred embodiment, the mammal includes a human or non-human mammal.

In another preferred embodiment, the non-human mammal includes rodents (such as mice, rats, or rabbits) and primates (such as monkeys).

In another preferred embodiment, the astrocytes are derived from the striatum, substantia nigra, spinal cord, dorsal midbrain or cerebral cortex, preferably, the astrocytes are derived from the striatum .

In another preferred embodiment, the astrocytes include striatal astrocytes.

In another preferred embodiment, the astrocytes are astrocytes of brain tissue.

In another preferred embodiment, the inhibitor is selected from the group consisting of antibodies, small molecule compounds, microRNA, siRNA, shRNA, antisense oligonucleotides, nucleic acid aptamers, gene editors, or combinations thereof.

In another preferred embodiment, the gene editor includes a DNA gene editor and an RNA gene editor.

In another preferred embodiment, the gene editor includes optional gRNA and gene editing protein.

In another preferred embodiment, the gene editor is expressed by a glial cell-specific promoter (for example, GFAP promoter).

In another preferred example, the gene editor includes two or more gNRA and gene editing proteins.

In another preferred example, the gRNA is RNA that guides the gene editing protein to specifically bind to the Ptbp1 gene.

In another preferred embodiment, the gRNA guide gene editing protein specifically binds to the mRNA of the Ptbp1 gene.

In another preferred embodiment, the gene editing protein is selected from the group consisting of Cas13d, CasRx, Cas13e, CRISPR/Cas9, Cpf1, Cas9, Cas13a, Cas13b, Cas13c, Cas13f, RNA targeted gene editing protein, or a combination thereof.

In another preferred embodiment, the gene editing protein is CasRx, and the nucleotide sequence of gRNA is selected from the group consisting of SEQ ID NO.: 1, 2, 3, 4, 5, and 6.

In another preferred embodiment, the source of the gene editing protein is selected from the group consisting of Streptococcus pyogenes, Staphylococcus aureus, Acidaminococcus sp, Lachnospiraceae bacterium ), Ruminococcus Flavefaciens, or a combination thereof.

In another preferred example, the Ptbp1 is derived from mammals; preferably, it is derived from humans, mice, rats, or rabbits; more preferably, it is derived from humans.

In another preferred example, the Ptbp1 gene includes wild-type Ptbp1 gene and mutant Ptbp1 gene.

In another preferred example, the mutant type includes a mutant form in which the function of the encoded protein is not changed after mutation (that is, the function is the same or substantially the same as that of the wild-type encoded protein).

In another preferred example, the polypeptide encoded by the mutant Ptbp1 gene is the same or substantially the same as the polypeptide encoded by the wild Ptbp1 gene.

In another preferred example, the mutant Ptbp1 gene includes homology of ≥80% (preferably ≥90%, more preferably ≥95%, more preferably ≥98% compared with the wild Ptbp1 gene) Or 99%) polynucleotides.

In another preferred embodiment, the mutant Ptbp1 gene is included in the 5'end and/or 3'end of the wild-type Ptbp1 gene, truncated or added 1-60 (preferably 1-30, more preferably 1 -10) nucleotide polynucleotides.

In another preferred example, the Ptbp1 gene includes a cDNA sequence, a genome sequence, or a combination thereof.

In another preferred embodiment, the Ptbp1 protein includes active fragments of Ptbp1 or derivatives thereof.

In another preferred example, the homology of the active fragment or its derivative with Ptbp1 is at least 90%, preferably 95%, more preferably 98%, 99%.

In another preferred embodiment, the active fragment or derivative thereof has at least 80%, 85%, 90%, 95%, 100% of Ptbp1 activity.

In another preferred embodiment, the amino acid sequence of the Ptbp1 protein is selected from the following group:

(i) A polypeptide having the amino acid sequence shown in SEQ ID NO.: 11;

(ii) The amino acid sequence shown in SEQ ID NO.: 11 is formed by the substitution, deletion or addition of one or a few (such as 1-10) amino acid residues, and those with the protein function are formed by ( i) Derived polypeptide; or

(iii) The homology between the amino acid sequence and the amino acid sequence shown in SEQ ID NO.: 11 is ≥90% (preferably ≥95%, more preferably ≥98% or 99%), and a polypeptide having the protein function.

In another preferred example, the nucleotide sequence of the Ptbp1 gene is selected from the following group:

(a) A polynucleotide encoding the polypeptide shown in SEQ ID NO.: 11;

(b) A polynucleotide whose sequence is shown in SEQ ID NO.: 12;

(c) A polynucleotide whose nucleotide sequence has a homology of ≥95% (preferably ≥98%, more preferably ≥99%) with the sequence shown in SEQ ID NO.: 12;

(d) Truncate or add 1-60 (preferably 1-30, more preferably 1-10) nuclei at the 5'end and/or 3'end of the polynucleotide shown in SEQ ID NO.: 12 Glycated polynucleotide;

(e) A polynucleotide complementary to any of the polynucleotides described in (a) to (d).

In another preferred embodiment, the ptbp1 protein is shown in SEQ ID NO.: 11.

In another preferred embodiment, the nucleic acid encoding the ptbp1 protein is shown in SEQ ID NO.: 12.

In another preferred example, the region targeted by the ptbp1 gene or the inhibitor of the encoded protein (such as the gene editing protein) is the 4758-4787 and/or 5381-5410 positions of the ptbp1 gene sequence.

In another preferred embodiment, the inhibitor of the ptbp1 gene or its encoded protein inhibits the activity and/or expression of ptbp1.

In another preferred embodiment, the concentration of the inhibitor gene or its encoded protein ptbp1 (virus titer)> 1 × 10 ^13, preferably, is ^{^{1 × 10 13 -1 × 10 14}} .

In another preferred example, the inhibitory rate of the ptbp1 gene or its encoded protein inhibitor on the activity and/or expression of ptbp1 is greater than 90%, preferably, 90%-95%.

In another preferred embodiment, the inhibitor targets astrocytes in brain tissue.

In another preferred embodiment, the inhibitor targets MG cells of the retina.

In another preferred embodiment, the neurodegenerative disease includes Parkinson's disease.

The second aspect of the present invention provides a composition comprising:

(a) A gene editing protein or an expression vector thereof, the gene editing protein is selected from the group consisting of CasRx, CRISPR/Cas9, Cpf1, Cas9, Cas13a, Cas13b, Cas13c, RNA targeted gene editing protein, or a combination thereof; and

(b) gRNA or an expression vector thereof, the gRNA is DNA or RNA that guides the gene editing protein to specifically bind to the Ptbp1 gene.

In another preferred embodiment, the nucleotide sequence of the gRNA is selected from the following group: SEQ ID NO.: 1, 2, 3, 4, 5, and 6.

In another preferred embodiment, the composition includes a pharmaceutical composition.

In another preferred embodiment, the composition further includes:

(c) Other drugs to prevent and/or treat neurodegenerative diseases.

In another preferred embodiment, the composition further includes:

(d) Other drugs used to treat neurological diseases related to functional neuron death.

In another preferred embodiment, the composition further includes:

(e) Other drugs to prevent and/or treat retinal diseases.

In another preferred embodiment, the expression vector of the gene editing protein includes a vector targeting glial cells.

In another preferred embodiment, the expression vector of the gene editing protein includes a vector targeting astrocytes of brain tissue.

In another preferred embodiment, the expression vector of the gene editing protein includes a vector targeting retinal MG cells.

In another preferred embodiment, the expression vector includes a viral vector.

In another preferred example, the viral vector is selected from the following group: adeno-associated virus (AAV), adenovirus, lentivirus, retrovirus, herpes virus, SV40, poxvirus, or a combination thereof.

In another preferred embodiment, the vector is selected from the following group: lentivirus, adenovirus, adeno-associated virus (AAV), or a combination thereof, preferably, the vector is adeno-associated virus (AAV).

In another preferred embodiment, the carrier includes AAV2 or AAV9.

In another preferred embodiment, the dosage form of the composition is selected from the group consisting of a lyophilized preparation, a liquid preparation, or a combination thereof.

In another preferred embodiment, the dosage form of the composition is a liquid preparation.

In another preferred embodiment, the dosage form of the composition is an injection dosage form.

In another preferred embodiment, other drugs for preventing and/or treating neurodegenerative diseases are selected from the following group: dopamine prodrugs, non-ergot dopamine receptor agonists, monoamine oxidase B inhibitors, or combinations thereof.

In another preferred embodiment, the composition is a cell preparation.

In another preferred example, the expression vector of the gene editing protein and the expression vector of gRNA are the same vector or different vectors.

In another preferred example, the weight ratio of the component (a) to the component (b) is 100:1 to 0.01:1, preferably, 10:1 to 0.1:1, more preferably, 2: 1-0.5:1.

In another preferred embodiment, the content of the component (a) in the composition is 0.001%-99%, preferably, 0.1%-90%, more preferably, 1%-70%.

In another preferred embodiment, in the composition, the content of the component (b) is 0.001%-99%, preferably, 0.1%-90%, more preferably, 1%-70%.

In another preferred example, the content of the component (c) in the composition is 1%-99%, preferably, 10%-90%, more preferably, 30%-70%.

In another preferred example, in the composition, the component (a), component (b) and optional component (c) account for 0.01-99.99 wt% of the total weight of the composition, which is greater than Preferably 0.1-90wt%, more preferably 1-80wt%.

The third aspect of the present invention provides a medicine kit including:

(a1) The first container, and the gene editing protein or its expression vector in the first container, or a medicine containing the gene editing protein or its expression vector, the gene editing protein is selected from the group consisting of Cas13d, CasRx, Cas13e, CRISPR/Cas9, Cpf1, Cas9, Cas13a, Cas13b, Cas13c, Cas13f, RNA targeted gene editing protein, or a combination thereof;

(b1) The second container, and the gRNA or its expression vector, or a drug containing the gRNA or its expression vector, in the second container, the gRNA is DNA or RNA that guides the gene editing protein to specifically bind to the Ptbp1 gene.

In another preferred example, the region targeted by the gRNA is positions 4758-4787 and/or positions 5381-5410 of the Ptbp1 gene sequence.

In another preferred embodiment, the kit further includes:

(c1) The third container, and other drugs for preventing and/or treating neurodegenerative diseases, and/or containing other drugs for preventing and/or treating retinal diseases, and/or containing other drugs in the third container Drugs for neurological diseases related to functional neuronal death.

In another preferred embodiment, the first container, the second container, and the third container are the same or different containers.

In another preferred embodiment, the medicine in the first container is a unilateral preparation containing gene editing protein or its expression vector.

In another preferred embodiment, the medicine in the second container is a unilateral preparation containing gRNA or its expression vector.

In another preferred embodiment, the medicine in the third container is a unilateral preparation containing other medicines intended to treat neurological diseases related to functional neuron death.

In another preferred embodiment, the dosage form of the drug is selected from the group consisting of a lyophilized preparation, a liquid preparation, or a combination thereof.

In another preferred embodiment, the dosage form of the drug is an oral dosage form or an injection dosage form.

In another preferred embodiment, the kit also contains instructions.

The fourth aspect of the present invention provides a composition according to the second aspect of the present invention or the use of the kit according to the third aspect of the present invention to prepare a medicine for the treatment of neurological diseases related to functional neuron death .

In another preferred embodiment, the composition, the concentration of the role of protein or gene expression vector editing (viral titer)> 1 × 10 ^13, ^{preferably, 1 × 10 13 -1 × 10} 14.

In another preferred embodiment, the composition or expression of the gRNA concentration of the carrier (viral titer)> 1 × 10 ^13, ^{preferably, 1 × 10 13 -1 × 10} 14.

In another preferred embodiment, in the pharmaceutical composition, the concentration (viral titer) of the other drugs for treating neurological diseases related to functional neuron death is> 1×10 ¹³ , preferably, 1×10 ¹³ —1×10 ¹⁴ .

In another preferred embodiment, the composition or kit includes (a) gene editing protein or its expression vector; and (b) gRNA or its expression vector; and (c) optionally other functional nerves Drugs for neurological diseases related to death; and (d) pharmaceutically acceptable carriers.

In another preferred embodiment, in the composition or kit, (a) gene editing protein or its expression vector; and (b) gRNA or its expression vector; and (c) optionally other functionalities for treatment The drugs for neuron death-related neurological diseases account for 0.01-99.99 wt% of the total weight of the composition or kit, preferably 0.1-90 wt%, more preferably 1-80 wt%.

The fifth aspect of the present invention provides a method for promoting the differentiation of glial cells into functional neurons, including the steps:

Glial cells are cultured in the presence of inhibitors of Ptbp1 gene or RNA or its encoded protein or the composition of the second aspect of the present invention, thereby promoting the differentiation of glial cells into functional neurons.

In another preferred embodiment, the glial cells are cells in vitro.

In another preferred embodiment, the effect of the concentration of the gene or its encoded protein Ptbp1 inhibitors (viral titer)> 1 × 10 ^13, ^{preferably, 1 × 10 13 -1 × 10} 14.

In another preferred embodiment, the effect of the concentration of composition 2 (titer) 1 × 10 ^13, ^{preferably, 1 × 10 13 -1 × 10} 14 claim>.

The sixth aspect of the present invention provides a method for preventing and/or treating neurological diseases related to functional neuron death, including:

An inhibitor of Ptbp1 gene or RNA or its encoded protein, or the composition according to the second aspect of the present invention, or the kit according to the third aspect of the present invention is administered to a subject in need.

In another preferred example, the subject includes a human or non-human mammal suffering from a neurological disease related to functional neuron death.

In another preferred embodiment, the non-human mammals include rodents and primates, preferably mice, rats, rabbits, and monkeys.

The seventh aspect of the present invention provides a method for screening candidate compounds for the prevention and/or treatment of neurological diseases related to functional neuron death, the method comprising the steps:

(a) In the test group, add the test compound to the cell culture system, and observe the expression (E1) and/or activity (A1) of Ptbp1 in the cells of the test group; in the control group, in the same cell No test compound is added to the culture system, and the expression (E0) and/or activity (A0) of Ptbp1 in the cells of the control group is observed;

Wherein, if the expression level (E1) and/or activity (A1) of cells in the test group is significantly lower than that of the control group, it indicates that the test compound is a preventive and/or inhibitory effect on the expression and/or activity of Ptbp1 Candidate compounds for the treatment of neurological diseases related to functional neuronal death.

In another preferred example, the expression level of Ptbp1 is obtained by qPCR.

In another preferred embodiment, the method further includes the steps:

(b) For the candidate compound obtained in step (a), further test its promoting effect on the differentiation of glial cells into functional neurons; and/or further test whether it has a down-regulation effect on the Ptbp1 gene.

In another preferred embodiment, the method includes step (c): applying the candidate compound determined in step (a) to a mammalian model, and determining its effect on the mammal.

In another preferred embodiment, the mammal is a mammal suffering from a neurological disease related to functional neuronal death.

In another preferred embodiment, the "significantly lower" means E1/E0≤1/2, preferably,≤1/3, more preferably≤1/4.

In another preferred example, the "significantly lower" means that A1/A0≤1/2, preferably,≤1/3, more preferably≤1/4.

In another preferred embodiment, the cells include glial cells.

In another preferred embodiment, the cell is a cell cultured in vitro.

In another preferred embodiment, the method is non-diagnostic and non-therapeutic.

The eighth aspect of the present invention provides a method for promoting the differentiation of astrocytes into dopamine neurons, including the steps:

In the presence of an inhibitor of Ptbp1 gene or RNA or its encoded protein or the composition according to the second aspect of the present invention, astrocytes are cultured to promote the differentiation of astrocytes into dopamine neurons.

In another preferred embodiment, the astrocytes include striatal astrocytes.

In another preferred embodiment, the astrocytes are astrocytes of brain tissue.

In another preferred embodiment, the astrocytes are cells in vitro.

In another preferred embodiment, the concentration of the combined action (viral titer)> 1 × 10 ^13, ^{preferably, 1 × 10 13 -1 × 10} 14.

In another preferred embodiment, the method is a non-diagnostic and non-therapeutic method.

The ninth aspect of the present invention provides a method for promoting the differentiation of Müller glial cells into optic ganglion cells, which comprises the steps of: in the presence of an inhibitor of Ptbp1 gene or RNA or its encoded protein or the composition of the second aspect of the present invention This promotes the differentiation of retinal Muller glial cells into optic ganglion cells.

In another preferred embodiment, the concentration of the action or inhibitors Ptbp1 gene encoding a protein or RNA (viral titer)> 1 × 10 ^13, ^{preferably, 1 × 10 13 -1 × 10} 14.

It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described in the following (such as the embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, I will not repeat them here.

Description of the drawings

Figure 1 shows that CasRx can specifically knock down Ptbp1 mRNA1 in vitro. (A) Schematic diagram of CasRx-mediated Ptbp1 mRNA knockdown. (B) The schematic diagram shows the target sites of six gRNAs in the Ptbp1 gene. (C and D) Knockdown efficiency of different combinations of gRNA. gRNA 5 and 6 showed the highest knockout efficiency in N2a cells (C) and astrocytes (D). The number above indicates the number of repetitions for each group. All values are expressed as mean±SEM. (E and F) CasRx-Ptbp1 can specifically knock down Ptbp1. N2a cells (E), n=4 independent repeats; astrocytes (F), n=2 independent repeats.

Figure 2 shows the specificity and expression of AAV, the closure of GFP expression over time, and the subtype of transformed RGC, which is related to Figure 1. _{(A) Compared with the CasRx control (x-axis), the expression level of log 2} (FPKM+1) values of all detected genes in the RNA-seq library of CasRx-Ptbp1 (y-axis). N2a cells, n=4 independent repeats; astrocytes, n=2 independent repeats. Typical neuron-derived genes are marked as black dots. (B) Specificity of AAV-GFAP-GFP-Cre. AAV-GFAP-GFP-Cre drives GFP expression and unlocks tdTomato expression in the MG of Ai9 mice. Sox9 is MG specific mark. Scale bar, 50 microns. (C) Determination of AAV expression. The percentage of GFP+ cells expressing tdTomato and the percentage of tdTomato+ cells expressing Sox9. All values are expressed as mean±SEM. (D) qPCR analysis confirmed that the infected retina expressed AAV-GFAP-CasRx and AAV-GFAP-CasRx-Ptbp1. The number above indicates the number of repetitions for each group. All values are expressed as mean±SEM. (E) MG-induced RGC will eventually turn off GFP expression over time. scale. The experiment was repeated 6 times independently for each group of 20 microns, and the results were similar. (FH) Staining of Foxp2, Brn3c and PV. Please note that Foxp2, Brn3c and PV are the markers of RGC subtype F-RGC, type 3 RGC and PV-RGC, respectively. The yellow arrow indicates the co-localization of tdTomato+ cells with different markers, and the white arrow indicates the co-localization of tdTomato+ cells with different markers. Scale bar, 20 microns. The experiment was repeated 3 times in each group, and the results were similar.

Figure 3 shows the combination of Ptbp1 transforming MG into RGC in the intact mature retina. (A) Schematic diagram of MG to RGC conversion. Vector I (AAV-GFAP-GFP-Cre) encodes Cre recombinase and GFP driven by MG-specific promoter GFAP, and vector II (AAV-GFAP-CasRx-Ptbp1) encodes CasRx and gRNA. To induce RGC, AAV-GFAP-CasRx-Ptbp1 or the control vector AAV-GFAP-CasRx and AAV-GFAP-GFP-Cre were injected into the retina (5-week-old Ai9 mice). Check for the occurrence of conversion about one month after injection. ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner plexiform layer; IPL, inner plexiform layer; GCL, ganglion cell layer. (B) Representative image showing co-localization of tdTomato and Brn3a in GCL (dashed line). The white arrow indicates the end of MG that is not co-localized with Brn3a, and the yellow arrow indicates the co-localization of tdTomato and Brn3a in the retina injected with AAV-GFAP-GFP-Cre and AAV-GFAP-CasRx-Ptbp1. Brn3a is a specific marker of RGC. Scale bar, 20 microns. (C) The number ^{of tdTomato +} or tdTomato ⁺ Brn3a ⁺ cells in GCL at 1 month after AAV injection. AAV-GFAP-GFP-Cre plus AAV-GFAP-CasRx, n=6 retinas; AAV-GFAP-GFP-Cre plus AAV-GFAP-CasRx-Ptbp1, n=7 retinas. Data are expressed as mean±SEM, *p<0.05, **p<0.01, **p<0.001, unpaired t test. (D) Representative image showing the co-localization of tdTomato with another specific marker of RGC in GCL, Rbpms. The yellow arrow indicates the co-localization of tdTomato and Rbpms. Scale bar, 20 microns. (E) The number of tdTomato+ or tdTomato+Rbpms+ cells in GCL at 1 month after AAV injection. AAV-GFAP-GFP-Cre plus AAV-GFAP-CasRx, n=6 retinas; AAV-GFAP-GFP-Cre plus AAV-GFAP-CasRx-Ptbp1, n=8 retinas. Data are expressed as mean±SEM, *p<0.05, **p<0.01, ***p<0.001, unpaired t test.

Figure 4 shows that knockdown of Ptbp1 converts MG to RGC in the intact retina of C57BL mice, which is related to Figure 3.

(A) Schematic diagram of induction of RGC from MG. Vector 1 (GFAP-mCherry) expresses mCherry driven by MG-specific promoter GFAP, and vector 2 (AAV-EFS-CasRx-Ptbp1) expresses gRNA and CasRx under the promoter of the spectrum. To induce RGC, AAV-GFAP-mCherry was injected into the retina, and AAV-EFS-CasRx-Ptbp1 or the control virus AAV-GFAP-mCherry was injected at the same time. Check the occurrence of conversion 2-3 weeks after injection. (B) Representative image showing the co-localization of mCherry and MG marker Sox9, indicating that AAV-GFAP-mCherry is specifically expressed in MG. Scale bar, 50 microns. (C, D) Representative images showing mCherry+Brn3a+ and mCherry+Rbpms+ cells in GCL. Each group n=3 retinas. Scale bar, 50 microns. (E) MCherry+ cells similar to RGC produce electrophysiological responses to LED light.

Figure 5 shows that knocking down Ptbp1 converts MG into amacrine cells, which is related to Figure 3. (A) tdTomato+Pax6+ cells were observed in the intact retina of Ai9 mice injected with AAV-GFAP-CasRx-Ptbp1. The green arrow indicates that the tdTomato+ cells are not co-localized with Pax6, and the yellow arrow indicates that Pax6 and tdTomato are co-localized. Please note that Pax6 is a marker for amacrine cells. Scale bar, 20 microns. (B) No tdTomato+Prox1+ cells were observed. The arrow indicates that tdTomato cells will not co-localize with Prox1 (a marker for bipolar cells). Scale bar, 20 microns. (C) No tdTomato+ cells were observed in the photoreceptor cell layer (ONL). White arrows indicate tdTomato-positive RGC-like cells in GCL, yellow arrows indicate tdTomato+protamine-like cells in INL, and green arrows indicate tdTomato+ projections of MG. Scale bar, 20 microns. Each group independently repeated the experiment at least 3 times, with similar results.

Figure 6 shows the induction of MG to RGC conversion in a mouse model of NMDA-induced retinal damage. (A) Experimental design. Intravitreal injection of NMDA (200mM, 1.5mL) into Ai9 mice aged 4-8 weeks caused retinal damage. Two to three weeks after NMDA injection, AAV is injected under the retina. Immunostaining and behavioral tests were performed one month after AAV injection. (B) NMDA injection basically killed most of the RGCs in GCL. Scale bar, 50 microns. (C) Co-localization of tdTomato and Brn3a. The yellow arrow indicates the co-localization of Brn3a and tdTomato in GCL. n=6 retinas, scale bar, 20 microns. (D) The number of Brn3a+ or tdTomato+ or tdTomato+Brn3a+ cells in GCL. Undamaged retina, n=6 retinas; GFAP-CasRx plus GFAP-GFP-Cre, n=6 retinas; GFAP-CasRx-Ptbp1 plus GFAP-GFP-Cre, n=7 retinas. Data are expressed as mean±SEM, *p<0.05, **p<0.01, ***p<0.001, unpaired t test. (E) Co-localization of tdTomato and Rbpms. The yellow arrow indicates the co-localization of Rbpms and tdTomato in GCL injected with GFAP-CasRx-Ptbp1 plus GFAP-GFP-Cre. Scale bar, 20 microns. (F) The number of Rbpms+ or tdTomato+ or tdTomato+Rbpms+ cells in GCL. Uninjured retina, n=6 retinas; GFAP-CasRx plus GFAP-GFP-Cre, n=7 retinas; GFAP-CasRx-Ptbp1 plus GFAP-GFP-Cre, n=7 retinas. Data are expressed as mean±SEM, *p<0.05, **p<0.01, ***p<0.001, unpaired t test. (G) Image shows representative RGC-like tdTomato+ cells recorded under a two-photon microscope. Scale bar, 20 microns. (H) Induced response of optic ganglion cells to light. A total of 8 cells were recorded, 6 of which showed the response to LED light. Among these cells, 5 are ON cells and 1 are OFF cells.

Figure 7 shows the progress of the MG to RGC conversion, which is related to Figure 6. (A) Representative images showing the conversion of MG to RGC at five different time points (without NMDA injection) in the intact retina. The arrow indicates induced RGC. Scale bar, 20 microns. The experiment was repeated independently ≥3 times with similar results. Please note that representative pictures in "2 months" are also shown in Figures 2B and 2D. (B) The absolute number of tdTomato+Brn3a+ and tdTomato+Rbpms+ cells in GCL. Note that the values in "1 month" are also shown in Figures 1C and 3E. All values are expressed as mean±SEM. (C) Representative image showing the intermediate stage of induced cells 1.5 weeks after AAV injection (white arrow). Each group n>=3 mice. Please note that the intermediate unit usually loses its projection in ONL. Scale bar, 10 microns. The experiment was repeated independently ≥3 times with similar results. (D) Representative images showing the conversion of MG to RGC in the retina damaged by NMDA at four different time points. The arrow indicates induced RGC. Scale bar, 20 microns. Please note that the representative images in "3 months" are also shown in Figures 3C and 3E. The experiment was repeated independently ≥2 times, with similar results.

Figure 8 shows that the converted RGC can be projected to the brain and partially restored visual function. (A) Schematic diagram of the visual pathway. RGC sends axons through the optic nerve and transmits optic nerve signals to the dorsal geniculate nucleus and superior colliculus outside the retina. (B) Retina tile. Yellow arrows indicate MG-derived tdTomato-positive RGC axons. Scale bar, 100 microns. The experiment was repeated 3 times in each group, and the results were similar. (C) Representative image showing tdTomato+ axons of RGC induced in the optic nerve. Scale bar, 200 microns. Each group was repeated 5 times independently, with similar results. (D and E) Representative images show that strong signals are observed in the contralateral dorsal geniculate nucleus (D) and superior colliculus (E) (target area of RGC projection in the brain). Each group was repeated 4 times independently, with similar results. Note that the ipsilateral dorsal geniculate nucleus and SC show weak tdTomato+ signals. Scale bars, 500 microns (left), 50 microns (right). (F) Schematic diagram of VEP recording. (G) VEP issuance in the primary visual cortex. The responses from the same group of mice are shown, with each line representing a retina. The top of the histogram represents the number of retinas in each group. (H) Wild type (WT, n=8 retinas), NMDA and AAV-GFAP-mCherry (n=12 retinas), NMDA, AAV-GFAP-mCherry and AAV-GFAP-CasRx (n=11 retinas) , And NMDA, AAV-GFAP-mCherry and AAV-GFAP-CasRx-Ptbp1 (n=8 retinas). Each point represents a mouse. Data are expressed as mean±SEM, *p<0.05, **p<0.01, ***p<0.001, unpaired t test. (I) Design of dark/light preference test. Please note that both eyes were treated with NMDA and the same AAV was injected 2 weeks after the NMDA injection. (J) Percentage of time spent in the dark room. WT, n=13 mice; NMDA and GFAP-mCherry, n=14 mice; NMDA, AAV-GFAP-mCherry and AAV-GFAP-CasRx, n=12 mice; NMDA, AAV-GFAP-mCherry And AAV-GFAP-CasRx-Ptbp1, n=12 mice. All values are expressed as mean±SEM; unpaired t-test; *p<0.05, **p<0.01, ***p<0.001.

Figure 9 shows the projection process of induced RGCs to the optic nerve and brain. (A) Representative images are shown at five different time points (1 week, 1.5 weeks, 2 weeks, 3 weeks and 1 month). The tdTomato+ axon (yellow arrow) was first seen 1.5 weeks after AAV injection. Scale bar, 50 microns. The experiment was repeated 3 times independently, with similar results. (B) The density of tdTomato+ axons (yellow arrows) in the dorsal geniculate nucleus gradually increases. Note that 1.5 weeks after AAV injection, tdTomato+ axons were first observed in the contralateral dorsal geniculate nucleus. Scale bars, 500 microns (top), 50 microns (bottom). The experiment was repeated 3 times independently, with similar results. (C) The projection process of tdTomato + axon (yellow arrow) to SC. Note that 2 weeks after the AAV injection, tdTomato+ axons were first observed in the contralateral SC. Scale bars, 500 microns (top), 50 microns (bottom). The experiment was repeated 3 times independently, with similar results. (D) The schematic diagram shows the gradual projection process of induced RGC.

Figure 10 shows the progression of RGC projection induced in the damaged retina, related to Figure 9. (A) Representative images show that at three different time points (1 week, 2 weeks, 3 weeks), NMDA-induced tdTomato+ axons in the optic nerve gradually increased. Scale bar, 50 microns. The experiment was repeated 2 times independently, with similar results. (B) The density of tdTomato+ axons (yellow arrows) in the dorsal geniculate nucleus gradually increases. Scale bars, 500 microns (top), 50 microns (bottom). The experiment was repeated 2 times independently, with similar results. (C) Projection progress of tdTomato+axons (yellow arrows) in the superior colliculus. Scale bars, 500 microns (top), 50 microns (bottom). The experiment was repeated 2 times independently, with similar results.

Figure 11 shows the conversion of glial cells to neurons mediated by CasRx. (A, B) Schematic diagram of injection strategy. The efficiency of transformation was evaluated about one month after injection. ST, striatum. (C) Co-localization of mCherry and GFAP. Percentage of mCherry+ cells expressing GFAP, n=3 mice. Scale bar, 20 microns. (D) One week after AAV injection, Flag (fused with CasRx) and GFAP co-localized. Scale bar, 20 microns. (E) One week after injection of AAV, the expression of Ptbp1 in the striatum (detected by the Ptbp1 antibody) was down-regulated. The expression of CasRx (fused with Flag) was detected by anti-Flag tag antibody. Each group n=4 mice. Scale bar, 10 microns. (F) Quantification of Ptbp1 fluorescence intensity using ImageJ. a.u. stands for arbitrary units. (G) Representative image of striatum. NeuN is a specific marker of mature neurons. The white arrow indicates that NeuN expression is not co-localized with mCherry, and the yellow arrow indicates that NeuN and mCherry are co-localized. Scale bar, 50 microns. (H) Percentage of mCherry+NeuN+ cells in mCherry+ cells (n=6 mice per group; t=-4.7, p<0.001). (I) The image shows that mCherry+NeuN+glutaminase positive cells (pink arrow) are adjacent to mCherry+NeuN+glutaminase negative cells (yellow arrow). Scale bar, 10 microns. (J) The percentage of mCherry+glutaminase+NeuN+ cells in mCherry+NeuN+ cells. N=5 mice. (K) Representative images show that mCherry+NeuN+ cells rarely co-localize with Somatostatin. The yellow arrow represents mCherry+NeuN+Somatostatin- cells, and the pink arrow represents mCherry+NeuN+Somatostatin+ cells. The control AAV showed the absence of mCherry+SST+ cells, indicating that SST+ cells could not be infected by AAV-GFAP-mCherry. The experiment was repeated 5 times independently, with similar results. Scale bar, 20 microns. (L) Representative images show that mCherry+NeuN+ cells are not co-localized with Palvabumin. The experiment was repeated 4 times independently, with similar results. Scale bar, 20 microns. (M) mCherry+TH+ cells (white arrow) are observed in the intact striatum. Scale bar, 20 microns. (N) Percentage of mCherry+TH+ cells in mCherry+ cells, n=5 mice per group. (O) Normally, mCherry+TH+ cells show very low NeuN expression (upper, white arrow) or undetectable level (lower, yellow arrow). Scale bar, 5 microns. The experiment was repeated 5 times independently, with similar results. All values are expressed as mean±SEM; unpaired t-test; *p<0.05, **p<0.01, ***p<0.001.

Figure 12 shows the conversion of astrocytes into dopamine neurons in Parkinson's model mice. (A and B) Summary of the experiment. Inject 6-OHDA unilaterally into the substantia nigra. After 3 weeks, AAV-GFAP-CasRx-Ptbp1 plus AAV-GFAP-mCherry, AAV-GFAP-CasRx plus AAV-GFAP-mCherry or normal saline were injected into the striae of the rat on the same side (relative to the 6-OHDA injection side). (B) Immunostaining was performed about 1 month or 3 months after AAV injection in the morphology. (C) Confocal images of transformed mCherry+TH+ (yellow arrow) and mCherry+DAT+ (yellow arrow) cells 1 month or 3 months after AAV injection. The orange arrows indicate the synapses of the transformed mCherry+TH+DAT+ cells. Please note that TH and DAT are specific markers of dopamine neurons. Scale bar, 50 microns or 10 microns. (D) Percentage of mCherry+TH+ cells in mCherry+ cells. AAV-GFAP-CasRx, 1 month: n=5 mice; AAV-GFAP-CasRx-Ptbp1, 1 month: n=5 mice; AAV-GFAP-CasRx-Ptbp1, 3 months: n= 3 mice. (E) The percentage of mCherry+TH+ cells in TH+ cells, n=5 mice per group. Scale bar, 50 microns. (F) Percentage of mCherry+DAT+ cells in mCherry+ cells. AAV-GFAP-CasRx, 1 month: n=5 mice; AAV-GFAP-CasRx-Ptbp1, 1 month: n=5 mice; AAV-GFAP-CasRx-Ptbp1, 3 months: n= 3 mice. (G) Percentage of mCherry+DAT+TH+ cells in mCherry+TH+ cells. AAV-GFAP-CasRx, 1 month: n=5 mice; AAV-GFAP-CasRx-Ptbp1, 1 month: n=5 mice; AAV-GFAP-CasRx-Ptbp1, 3 months: n= 3 mice. (H) The representative image shows that ALDH1A1 and GIRK2 expression are co-localized with mCherry+TH+ (yellow arrow), while Calbindin expression (orange arrow) is not co-localized with mCherry+DAT+. ALDH1A1 and GIRK2 are specific markers of dopamine neurons in SNc A9, and calbindin is a specific marker of dopamine neurons in VTA. Each group n=3 mice. Scale bar, 50 microns. (I) The percentage of mCherry+ALDH1A1+, mCherry+GIRK2+ and mCherry+calbindin+ cells in mCherry+ cells. Each group n=3 mice. (J) Percentages of mCherry+TH+ALDH1A1+ and mCherry+TH+GIRK2+ in mCherry+TH+ cells; and mCherry+DAT+calbindin+ cells in mCherry+DAT+ cells. Each group n=3 mice. (K) Whole-cell recording (n=22 cells) in striatal slices. This figure shows the ability of neuron-like mCherry+ cells to generate repetitive action potentials (20 out of 22 cells) and to rectify (4 out of 10 cells, green). (L) Image shows spontaneous synaptic current induced by neurons. (M) Hyperpolarized voltage-gated current. (N) Representative images show that mCherry+TH+ cells express VMAT2 (yellow arrow) and the percentage of mCherry+VMAT2+TH+ cells in mCherry+TH+ cells, n=3 mice. Scale bar, 20 microns. (o) The image shows that mCherry+ cells can take up FFN206 (blue) (a fluorescent dopamine derivative) one month after AAV injection. n>=10 slices per group. Scale bars, 30 microns (top), 20 microns (bottom). (P) FFN206 can be released in mCherry+ cells (yellow arrow). The image shows the release of FFN206 induced by high KCl. Scale bar, 10 microns. (Q) Statistical analysis of KCl-induced FFN206 release in sections injected with AAV-GFAP-mCherry plus AAV-GFAP-CasRx-Ptbp1, n=25mCherry+blue+ cells. 25 cells were analyzed from 5 sections (n=3 mice). All values are expressed as mean±SEM. Unpaired t-test; *p<0.05, **p<0.01, ***p<0.001.

Figure 13 shows that knockdown of Ptbp1 converts astrocytes into dopamine neurons in a mouse model of 6-OHDA-induced Parkinson's disease. (A) Experimental schematic diagram. (B) Staining shows the death of TH+ neurons (green) on the ipsilateral substantia nigra (relative to the 6-OHDA injection side). Scale bar, 100 microns. The experiment was repeated 12 times independently, with similar results. (C) DAT staining shows the disappearance of dopamine neuron fibers (green) in the ipsilateral striatum. Scale bar, 500 microns. The experiment was repeated independently >10 times with similar results. (D, E) Representative confocal images showing mCherry+TH+ and mCherry+DAT+ cells, and the quantification of mCherry+TH+ and mCherry+DAT+ cells at different time points after AAV injection. Each group n>=3 mice. Scale bar, 50 microns. Note that the data "GFAP-CasRx, 1 month", "GFAP-CasRx-Ptbp1, 1 month" and "GFAP-CasRx-Ptbp1, 3 months" are also shown in FIGS. 6C, 6D, and 6. Scale bar, 50 microns. (F) The absolute number of TH+ cells in Parkinson's disease model mice. (G) Confocal images of mCherry+TH+ cells and the percentage of mCherry+TH+ cells in TH+ cells, n=5 mice per group. Scale bar, 50 microns. (H) Percentage of mCherry+TH+ cells in mCherry+ cells. Note that the data is also shown in Figure 6D and S6N. (I) The absolute number of DAT+ cells in PD model mice. (J, K) Confocal images of mCherry+DDC+ cells and the percentage of mCherry+DDC+ cells in mCherry+ cells, n=5 mice per group. DDC is a dopamine neuron marker. Scale bar, 50 microns. (L, M) Representative images show the co-localization of FOXA2 and mCherry (yellow arrow) and the percentage of mCherry+FOXA2+ cells in the cell. Each group n=5 mice. FOXA2 is a dopamine neuron marker. Scale bar, 30 microns. (N) Representative images show that mCherry+TH+ cells are not co-localized with representative striatal interneuron markers PV, SST and CR. The yellow arrows indicate mCherry+TH+ cells, and the blue arrows indicate PV+, SST+ or CR+ cells. Please note that SST is co-localized with mCherry but not with TH. This is consistent with the results in Figure S1H, indicating that knocking out Ptbp1 can sparsely induce SST+ neurons. The experiment was repeated 3 times independently, with similar results. Scale bar, 20 microns. (O) Comparison of net revolutions before and 1 month after AAV injection. The number above the dot indicates the number of mice in each group. Paired t test. The "1 month" data is also shown in Figure 7. (P) Net rotation (revolutions/min) caused by apomorphine injection. Each mouse was evaluated for behavior at 1 and 3 months, n=3 mice per group. Two-way ANOVA and Bonferroni's test. The "1 month" data is also shown in Figure 7. (Q) Net rotation (revolutions per minute) caused by amphetamine injection, n=3 mice per group. Two-way ANOVA and Bonferroni's test. The "1 month" data is also shown in Figure 7. All values are expressed as mean±SEM; unpaired t-test; *p<0.05, **p<0.01, ***p<0.001.

Figure 14 shows that the induced neurons alleviated the motor dysfunction in Parkinson's disease model mice. (A) Experimental design. (B) Net rotation caused by apomorphine injection (contralateral-ipsilateral). (C) Net rotation caused by amphetamine injection (ipsilateral-contralateral). (D) After systemic injection of amphetamine, the percentage of ipsilateral rotation relative to the total number of rotations (ipsilateral/total rotation). (E) The percentage of spontaneous touches on the same side relative to the total number of touches. (F) Rotary rod instrument test. The results are expressed as the time (seconds) the mouse stays on the accelerated rotating rod before falling. The numbers above the bars indicate the number of mice in each group. All values are expressed as mean±SEM. One-way analysis of variance followed by Tukey test. *p<0.05, **p<0.01, ***p<0.001.

detailed description

After extensive and in-depth research, the present inventors unexpectedly discovered for the first time that inhibiting the expression or activity of glial cells ptbp1 gene or RNA or its encoded protein can effectively induce glial cells to differentiate into functional neurons, thereby achieving therapeutic functions Neurological diseases related to the death of sexual neurons. On this basis, the inventor completed the present invention.

In the present invention, the degeneration of retinal ganglion cells (RGC) is the main cause of permanent blindness. The transdifferentiation of Müller glial cells (MG) into functional RGC can help restore vision. The inventors found that knocking down Ptbp1 by using the RNA-targeted CRISPR system CasRx in the retina of mature mice can directly convert MG into functional RGC. In addition, in a mouse model of retinal injury induced by NMDA (N-methyl-d-aspartic acid), the RGC transformed from MG achieves a functional projection to the central visual area and improves visual function . Therefore, Ptbp1 knockdown mediated by CasRx will be a promising treatment for retinal diseases caused by neurodegeneration.

This application uses CasRx, a recently characterized RNA targeting CRISPR system, to inhibit Ptbp1. CasRx-mediated regeneration avoids the appearance of substantial off-target effects induced by shRNA and the risk of permanent gene changes through DNA editing nucleases, and provides an excellent tool that can treat a variety of diseases.

As used herein, Müller glial cells (MG) are the main glial cells in the retinal tissue, and retinal ganglion cells (RGC) are nerve cells located in the innermost layer of the retina. Its dendrites are mainly connected with bipolar cells. Its axons extend to the optic nerve head to form the optic nerve.

Retinal disease is regarded as an eye disease. There are five common retinal diseases: ① Diseases of blood vessels and vascular system. Such as retinal vascular occlusion, arteriosclerosis, hypertension, blood disease and diabetic fundus disease. ② Inflammation of the retina. It is closely related to the mutual influence of choroiditis and optic neuritis. ③Retina detachment. Refers to the separation of the retinal nerve layer and the pigment epithelium. ④Retinal degeneration and malnutrition. Has genetic factors. ⑤ Retinal tumors. Among them, retinoblastoma is more common.

In the present invention, a preferred retinal disease is a retinal disease caused by neurodegeneration, and the symptoms are mainly manifested in decreased vision or blindness.

In the present invention, the gene editor includes a DNA gene editor and an RNA gene editor. In a preferred embodiment, the gene editor of the present invention includes a gene editing protein and optionally gRNA.

The term "reprogramming" or "transdifferentiation" may refer to the process of producing cells of a specific lineage (for example, neuronal cells) from different types of cells (for example, fibroblasts) without intermediate differentiation.

Nervous system diseases related to functional neuronal death

In the present invention, neurological diseases related to functional neuron death mainly include Parkinson's disease and visual disturbance caused by the death of optic ganglia.

In a preferred embodiment, neurological diseases related to functional neuronal degeneration include, but are not limited to, glaucoma, age-related RGC loss, optic nerve damage, retinal ischemia, Leber hereditary optic neuropathy, Alzheimer’s Disease, Huntington’s disease, schizophrenia, depression, drug use, movement disorders (such as chorea, hypercholesterolemia and movement disorders), motor neuron injury diseases (such as amyotrophic lateral sclerosis, spinal cord injury), bipolar disorder Disease, autism spectrum disorder (ASD), dysfunction, Parkinson’s disease.

Astrocyte

Astrocytes are the most abundant type of cells in the mammalian brain. They perform many functions, including biochemical support (such as forming a blood-brain barrier), providing nutrients for neurons, maintaining extracellular ion balance, and participating in repair and scar formation after brain and spinal cord injury. According to the content of glial filaments and the shape of cell processes, astrocytes can be divided into two types: fibrous astrocytes (fibrous astrocytes) are mostly distributed in the white matter of the brain and spinal cord, with slender protrusions and fewer branches , The cytoplasm contains a lot of glial filaments; protoplasmic astrocytes (protoplasmic astrocytes) are mostly distributed in the gray matter, with stubby cell processes and many branches.

The astrocytes that can be used in the present invention are not particularly limited, and include various astrocytes derived from the central nervous system of mammals, such as from the striatum, spinal cord, dorsal midbrain or cerebral cortex, preferably , From the striatum.

Functional neuron

In the present invention, a functional neuron may refer to a neuron capable of sending or receiving information through chemical or electrical signals. In some embodiments, functional neurons exhibit one or more functional properties of mature neurons present in the normal nervous system, including but not limited to: excitability (e.g., the ability to exhibit action potentials, such as rapid Rise and subsequent fall) (voltage or membrane potential across the cell membrane), form synaptic connections with other neurons, release of presynaptic neurotransmitters, and post-synaptic responses (e.g., excitatory postsynaptic current or inhibitory synaptic current Aftertouch current).

In some embodiments, the functional neuron is characterized by the expression of one or more markers of the functional neuron, including but not limited to synapsin, synaptophysin, glutamate decarboxylase 67 (GAD67), glutamine Acid decarboxylase 67 (GAD65), paralbumin, dopamine- and cAMP-regulated neuronal phosphoprotein 32 (DARPP32), vesicle glutamate transporter 1 (vGLUT1), vesicle glutamate transporter 2 (vGLUT2) , Acetylcholine, tyrosine hydroxylase (TH), dopamine, vesicle GABA transporter (VGAT) and γ-aminobutyric acid (GABA).

Dopamine neuron

Dopaminergic neuron (dopaminergic neuron) contains and releases dopamine (dopamine, DA) as a neurotransmitter. Dopamine is a catecholamine neurotransmitter and plays an important biological role in the central nervous system. Dopaminergic neurons in the brain are mainly concentrated in the substantria nigra pars compacta (SNc) of the midbrain and the ventral cover Area (ventral tegmental area, VTA), hypothalamus and periventricular. Many experiments have confirmed that dopaminergic neurons are closely related to many diseases of the human body, the most typical being Parkinson's disease.

Neurodegenerative diseases

Neurodegenerative diseases are diseases caused by the loss of neurons in the brain and spinal cord. Neurons are the most important part of the nervous system, and his death will eventually lead to dysfunction of the nervous system. After a patient suffers from a neurodegenerative disease, there will be mobility or cognitive impairment, and the development of the disease often leads to many complications, causing serious damage to the patient's life. Clinically, neurodegenerative diseases mainly include Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis. At present, the neurodegenerative diseases can only be relieved or delayed, and cannot be completely cured. Parkinson's disease (PD) is a serious neurodegenerative disease characterized by the loss of dopamine neurons in the substantia nigra of the midbrain.

Gene editor

Gene editing protein

In the present invention, the nucleotides of the gene editing protein can be obtained by genetic engineering techniques, such as genome sequencing, polymerase chain reaction (PCR), etc., and the amino acid sequence can be derived from the nucleotide sequence. The source of the wild-type gene editing protein includes (but is not limited to): Ruminococcus Flavefaciens, Streptococcus pyogenes, Staphylococcus aureus, and Acidaminococcus sp. , Lachnospiraceae bacterium (Lachnospiraceae bacterium).

In a preferred embodiment of the present invention, the gene editing protein includes, but is not limited to Cas13d, CasRx, Cas13e, CRISPR/Cas9, Cpf1, Cas9, Cas13a, Cas13b, Cas13c, Cas13f, RNA targeted gene editing protein.

ptbp1 protein and polynucleotide

In the present invention, the terms "protein of the present invention", "ptbp1 protein", "ptbp1 polypeptide" and "PTB" are used interchangeably, and all refer to a protein or polypeptide having an amino acid sequence of ptbp1. They include ptbp1 protein with or without starting methionine. In addition, the term also includes full-length ptbp1 and fragments thereof. The ptbp1 protein referred to in the present invention includes its complete amino acid sequence, its secreted protein, its mutant and its functionally active fragments.

The ptbp1 protein is a polypyrimidine domain binding protein 1, which is an RNA binding protein that regulates RNA splicing. At the same time, it also plays a very critical role in other functions of RNA.

In the present invention, the terms "ptbp1 gene", "ptbp1 polynucleotide" and "PTB gene" are used interchangeably, and all refer to a nucleic acid sequence having a ptbp1 nucleotide sequence.

The genome of the human ptbp1 gene is 14936bp in length (NCBI GenBank accession number is 5725).

The genome of the mouse ptbp1 gene is 10004bp in length (NCBI GenBank accession number is 19205).

The similarity of human and mouse ptbp1 at the DNA level is 88%, and the similarity of protein sequence is 84%. It should be understood that when encoding the same amino acid, the substitution of nucleotides in the codon is acceptable. In addition, it should be understood that when conservative amino acid substitutions are generated by nucleotide substitutions, nucleotide changes are also acceptable.

When the amino acid fragment of ptbp1 is obtained, a nucleic acid sequence encoding it can be constructed based on it, and specific probes can be designed based on the nucleotide sequence. The full-length nucleotide sequence or its fragments can usually be obtained by PCR amplification, recombination, or artificial synthesis. For the PCR amplification method, primers can be designed according to the ptbp1 nucleotide sequence disclosed in the present invention, especially the open reading frame sequence, and a commercially available cDNA library or a cDNA prepared by a conventional method known to those skilled in the art can be used. The library is used as a template to amplify the relevant sequences. When the sequence is long, it is often necessary to perform two or more PCR amplifications, and then splice the amplified fragments together in the correct order.

Once the relevant sequence is obtained, the recombination method can be used to obtain the relevant sequence in large quantities. This usually involves cloning it into a vector, then transferring it into a cell, and then isolating the relevant sequence from the proliferated host cell by conventional methods.

In addition, artificial synthesis methods can also be used to synthesize related sequences, especially when the fragment length is short. Usually, by first synthesizing multiple small fragments, and then ligating to obtain a very long fragment.

At present, the DNA sequence encoding the protein (or fragment or derivative thereof) of the present invention can be obtained completely through chemical synthesis. The DNA sequence can then be introduced into various existing DNA molecules (such as vectors) and cells known in the art.

Through conventional recombinant DNA technology, the polynucleotide sequence of the present invention can be used to express or produce recombinant ptbp1 polypeptide. Generally speaking, there are the following steps:

(1) Transform or transduce suitable host cells with the polynucleotide (or variant) encoding human ptbp1 polypeptide of the present invention, or with a recombinant expression vector containing the polynucleotide;

(2). Host cells cultured in a suitable medium;

(3). Separate and purify protein from culture medium or cells.

In the present invention, the ptbp1 polynucleotide sequence can be inserted into a recombinant expression vector. In short, any plasmid and vector can be used as long as it can replicate and stabilize in the host. An important feature of an expression vector is that it usually contains an origin of replication, a promoter, a marker gene, and translation control elements.

The methods well known to those skilled in the art can be used to construct an expression vector containing the ptbp1 coding DNA sequence and appropriate transcription/translation control signals. These methods include in vitro recombinant DNA technology, DNA synthesis technology, and in vivo recombination technology. The DNA sequence can be effectively linked to an appropriate promoter in the expression vector to guide mRNA synthesis. The expression vector also includes a ribosome binding site for translation initiation and a transcription terminator.

In addition, the expression vector preferably contains one or more selectable marker genes to provide phenotypic traits for selecting transformed host cells, such as dihydrofolate reductase for eukaryotic cell culture, neomycin resistance, and green Fluorescent protein (GFP), or tetracycline or ampicillin resistance for E. coli.

A vector containing the above-mentioned appropriate DNA sequence and an appropriate promoter or control sequence can be used to transform an appropriate host cell so that it can express the protein.

The host cell can be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Representative examples include: Escherichia coli, bacterial cells of the genus Streptomyces; fungal cells such as yeast; plant cells; insect cells; animal cells, etc.

Transformation of host cells with recombinant DNA can be performed by conventional techniques well known to those skilled in the art. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA can be harvested after the exponential growth phase and treated with the CaCl ₂ method. The steps used are well known in the art. Another method is to use MgCl ₂ . If necessary, transformation can also be performed by electroporation. When the host is a eukaryote, the following DNA transfection methods can be selected: calcium phosphate co-precipitation method, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.

The obtained transformants can be cultured by conventional methods to express the polypeptide encoded by the gene of the present invention. Depending on the host cell used, the medium used in the culture can be selected from various conventional mediums. The culture is carried out under conditions suitable for the growth of the host cell. After the host cells have grown to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.

The recombinant polypeptide in the above method can be expressed in the cell or on the cell membrane, or secreted out of the cell. If necessary, the physical, chemical, and other characteristics can be used to separate and purify the recombinant protein through various separation methods. These methods are well known to those skilled in the art. Examples of these methods include, but are not limited to: conventional renaturation treatment, treatment with protein precipitation agent (salting out method), centrifugation, osmotic cleavage, ultra-treatment, ultra-centrifugation, molecular sieve chromatography (gel filtration), adsorption layer Analysis, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography techniques and combinations of these methods.

Adeno-associated virus

Because Adeno-associated virus (AAV) is smaller than other viral vectors, is non-pathogenic, and can transfect dividing and undivided cells, gene therapy methods for genetic diseases based on AAV vectors have been affected. Widespread concern.

Adeno-associated virus (adeno-associated virus, AAV), also known as adeno-associated virus, belongs to the Parvoviridae dependent virus genus. It is the simplest type of single-stranded DNA-deficient virus found so far and requires a helper virus (usually Viruses) participate in replication. It encodes the cap and rep genes in the inverted repeat (ITR) at both ends. ITRs play a decisive role in virus replication and packaging. The cap gene encodes the viral capsid protein, and the rep gene is involved in virus replication and integration. AAV can infect a variety of cells.

Recombinant adeno-associated virus vector (rAAV) is derived from non-pathogenic wild-type adeno-associated virus. Due to its good safety, wide range of host cells (dividing and non-dividing cells), and low immunogenicity, it can express foreign genes in vivo. Long and other characteristics, it is regarded as one of the most promising gene transfer vectors and has been widely used in gene therapy and vaccine research worldwide. After more than 10 years of research, the biological characteristics of recombinant adeno-associated virus have been deeply understood, especially its application effects in various cells, tissues and in vivo experiments have accumulated a lot of data. In medical research, rAAV is used in the research of gene therapy for various diseases (including in vivo and in vitro experiments); at the same time, as a characteristic gene transfer vector, it is also widely used in gene function research, disease model construction, and gene preparation. Knockout mice and other aspects.

In a preferred embodiment of the present invention, the vector is a recombinant AAV vector. AAVs are relatively small DNA viruses that can integrate into the genome of the cells they infect in a stable and site-specific manner. They can infect a large range of cells without any effect on cell growth, morphology or differentiation, and they do not seem to be involved in human pathology. The AAV genome has been cloned, sequenced and characterized. AAV contains an inverted terminal repeat (ITR) region of approximately 145 bases at each end, which serves as the origin of replication of the virus. The rest of the genome is divided into two important regions with encapsidation functions: the left part of the genome containing the rep gene involved in viral replication and viral gene expression; and the right part of the genome containing the cap gene encoding the viral capsid protein.

AAV vectors can be prepared using standard methods in the art. Adeno-associated viruses of any serotype are suitable. Methods for purifying vectors can be found in, for example, U.S. Patent Nos. 6,566,118, 6,989,264, and 6,995,006, the disclosures of which are incorporated herein by reference in their entirety. The preparation of hybrid vectors is described in, for example, PCT Application No. PCT/US2005/027091, the disclosure of which is incorporated herein by reference in its entirety. The use of AAV-derived vectors for in vitro and in vivo gene transfer has been described (see, for example, International Patent Application Publication Nos. WO91/18088 and WO93/09239; U.S. Patent Nos. 4,797,368, 6,596,535 and 5,139,941, and European Patent No. 0488528, they are all incorporated herein by reference in their entirety). These patent publications describe various AAV-derived constructs in which the rep and/or cap genes are missing and replaced by the gene of interest, and these constructs are in vitro (into cultured cells) or in vivo (into the organism directly) ) The purpose of transporting the gene of interest. Replication-deficient recombinant AAV can be prepared by co-transfecting the following plasmids into a cell line infected with a human helper virus (such as adenovirus): the nucleic acid sequence of interest is flanked by two AAV inverted terminal repeats (ITR) Region plasmids, and plasmids carrying AAV encapsidation genes (rep and cap genes). The resulting AAV recombinants are then purified by standard techniques.

In some embodiments, the recombinant vector is capsidized to viral particles (e.g., including but not limited to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15 And AAV virus particles of AAV16). Therefore, the present disclosure includes recombinant virus particles (recombinant because they contain recombinant polynucleotides) containing any of the vectors described herein. Methods of producing such particles are known in the art and are described in US Patent No. 6,596,535.

ptbp1 inhibitor and pharmaceutical composition

Using the protein of the present invention, through various conventional screening methods, substances that interact with the ptbp1 gene or protein, especially inhibitors, can be screened out.

The ptbp1 inhibitor (or antagonist) that can be used in the present invention includes any substance that can inhibit the expression and/or activity of the ptbp1 gene or its encoded protein.

For example, the inhibitor of ptbp1 includes an antibody of ptbp1, antisense RNA of ptbp1 nucleic acid, siRNA, shRNA, miRNA, gene editor, or an activity inhibitor of ptbp1. A preferred inhibitor of ptbp1 refers to a gene editor capable of inhibiting the expression of ptbp1.

Preferably, the inhibitors of ptbp1 of the present invention include inhibitors that target positions 4758-4787 and/or positions 5381-5410 of the ptbp1 gene sequence. The ptbp1 inhibitor of the present invention acts on astrocytes or MG cells.

In a preferred embodiment, the methods and steps for inhibiting ptbp1 include using an antibody of ptbp1 to neutralize its protein, and using shRNA or siRNA or a gene editor carried by a virus (such as adeno-associated virus) to silence the ptbp1 gene.

The inhibition rate of ptbp1 is generally at least 50% or more inhibition, preferably 60%, 70%, 80%, 90%, 95% inhibition, which can be based on conventional techniques, such as flow cytometry, fluorescent quantitative PCR or Western Methods such as blot control and detect the inhibition rate of ptbp1.

The inhibitors of the ptbp1 protein of the present invention (including antibodies, antisense nucleic acids, gene editors and other inhibitors), when administered (administered) therapeutically, can inhibit the expression and/or activity of the ptbp1 protein, thereby inducing glue Plasma cells differentiate into functional neurons to treat neurological diseases related to functional neuronal degeneration. Generally, these substances can be formulated in a non-toxic, inert and pharmaceutically acceptable aqueous carrier medium, where the pH is usually about 5-8, preferably about 6-8, although the pH can be The nature of the formulated substance and the condition to be treated vary. The formulated pharmaceutical composition can be administered by conventional routes, including (but not limited to): local, intramuscular, intraperitoneal, intravenous, subcutaneous, intradermal, topical administration, autologous cell extraction and culture and reinfusion Wait.

The present invention also provides a pharmaceutical composition, which contains a safe and effective amount of the inhibitor of the present invention (such as antibody, gene editor, antisense sequence (such as siRNA), or inhibitor) and a pharmaceutically acceptable carrier or excipient Shape agent. Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. The pharmaceutical preparation should match the mode of administration. The pharmaceutical composition of the present invention can be prepared in the form of injection, for example, prepared by conventional methods with physiological saline or an aqueous solution containing glucose and other adjuvants. Pharmaceutical compositions such as tablets and capsules can be prepared by conventional methods. Pharmaceutical compositions such as injections, solutions, tablets and capsules should be manufactured under sterile conditions. The dosage of the active ingredient is a therapeutically effective amount, for example, about 1 μg-10 mg/kg body weight per day.

The main advantages of the present invention include:

(1) The present invention found for the first time that reducing the expression or activity of the Ptbp1 gene or its encoded protein in astrocytes can induce the differentiation of astrocytes into dopamine neurons, thereby preventing and/or treating neurodegeneration Diseases (such as Parkinson's disease).

(2) The present invention finds for the first time that using a gene editor (including gene editing protein and gRNA) to inhibit the expression of ptbp1 in astrocytes can make astrocytes transdifferentiate into dopamine neurons, which in turn is Parkinson’s Treatment provides a potential way.

(3) The present invention found for the first time that the induction of dopamine neurons alleviated the motor dysfunction in the Parkinsonian mouse model.

(4) The present invention finds for the first time that the RNA-targeted CRISPR system CasRx can avoid the risk of permanent DNA changes caused by traditional CRISPR-Cas9 editing. Therefore, CasRx-mediated RNA editing provides an effective means for the treatment of various diseases.

(5) The present invention directly converts MG into functional RGC by inhibiting the expression of Ptbp1 in the retina.

(6) The regenerated RGC can be integrated into the visual pathway and improve the visual function of the mouse model of RGC injury.

(7) The present invention uses the RNA-targeted CRISPR system CasRx to knock down Ptbp1, avoiding the occurrence of substantive off-target effects induced by shRNA and the risk of permanently changing genes, and provides an excellent tool that can treat a variety of diseases.

The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and not to limit the scope of the present invention. The experimental methods without specific conditions in the following examples usually follow conventional conditions, such as Sambrook et al., Molecular Cloning: Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions described in manufacturing The conditions suggested by the manufacturer. Unless otherwise specified, percentages and parts are weight percentages and parts by weight.

Unless otherwise specified, the materials and reagents used in the examples of the present invention are all commercially available products.

General method

Animal ethics: The use and feeding of animals conform to the guidelines of the Biomedical Research Ethics Committee of the Institute of Neuroscience, Chinese Academy of Sciences.

Guide RNA sequence

Guide 1: 5’-tttgtaccgactgctatgtctgggacgat-3’ (SEQ ID NO:1);

Guide 2: 5’-ggctggctgtctccagagggcaggtcaggt-3’ (SEQ ID NO: 2);

Guide 3: 5’-gtatagtagttaaccatagtgttggcagcc-3’ (SEQ ID NO: 3);

Guide 4: 5’-gctgtcggtcttgagctctttgtggttgga-3’ (SEQ ID NO: 4);

Guide 5: 5’-tgtagatgggctgtccacgaagcactggcg-3’ (SEQ ID NO: 5);

Guide 6: 5’-gcttggagaagtcgatgcgcagcgtgcagc-3’ (SEQ ID NO: 6).

Transient transfection of astrocytes and qPCR: isolated and cultured as previously described ¹ astrocytes. In short, astrocytes were seeded in 6-well plates. Using Lipofectamine 3000 (Thermo Fisher Scientific) according to standard procedures, 3 μg of gRNA-CasRx-GFP expressing vector was used for transient transfection. The control plasmid expresses non-targeted guidance. 1-2 days after transient transfection, GFP positive cells were collected by Flow Fluorescence Cell Sorting (FACS) and lysed for qPCR analysis: first use Trizol (Ambion) to extract RNA, and then use reverse transcription kit (HiScript for qPCR) Q RT SuperMix, Vazyme, Biotech) reverse transcription of RNA into cDNA. The amplification was followed by AceQ qPCR SYBR Green Master Mix (Vazyme, Biotech). The Ptbp1 qPCR primers are: forward, 5'-AGAGGAGGCTGCCAACACTA-3' (SEQ ID NO.: 13); reverse, 5'-GTCCAGGGTCACTGGGTAGA-3' (SEQ ID NO. 14).

Stereotactic injection: AAV8 (Figure 1) and AAV-PhP.eb (Figures 2 and 3) were used in this study. Stereotactic injection (C57BL / 6,1-3 months) ² method as described above. The titers of AAV-CasRx-Ptbp1 in Figure 1 and Figures 2, 3 are about 5×10e12 (2μl per injection) and 1.6×10e13 (2-3μl per injection). Inject AAV into the striatum (AP+0.8mm, ML±1.6mm and DV-2.8mm).

Immunofluorescence staining: Immunofluorescence staining was performed 5-6 weeks (Figure 1) or 3-4 weeks (Figures 2 and 3) after injection. After the mice were perfused, their brains were taken and fixed with 4% paraformaldehyde (PFA) overnight, and kept in 30% sucrose for at least 12 hours. The sections were frozen after embedding, and the section thickness was 35 μm. Before immunofluorescence staining, the brain sections were washed thoroughly with 0.1M phosphate buffer (PB). Primary antibodies: rabbit polyclonal NeuN antibody (Brain, 1:500, #ABN78, Millipore), rabbit polyclonal Tbr1 antibody (#NG1854874, Millipore), mouse TH antibody (1:300, MAB318, Millipore) and rabbit DAT antibody (1:100, MAB369, Millipore). Secondary antibodies: Donkey anti-mouse (#715-545-150, Jackson ImmunoResearch) and donkey anti-rabbit (#711-545-152, Jackson ImmunoResearch) were used in this study. After the antibody incubation, the sections were washed and covered with mounting media (Life Technology).

Electrophysiological recordings: after AAV injection electrophysiological recordings 5-6 weeks, ³ as previously described. In short, the mice were anesthetized and perfused into the heart, and their brains were put into carbon dioxide-filled NMDG artificial cerebrospinal fluid (aCSF) [NMDG aCSF(mM): NMDG 92, potassium chloride 2.5, sodium dihydrogen phosphate 1.25, bicarbonate Sodium 30, HEPES 20, glucose 25, thiourea 2, sodium ascorbate 5) at room temperature, sodium pyruvate 3, calcium chloride 0.5, magnesium sulfate 10]. After perfusion, the brain was extracted and placed in an ice-cold NMDG aCSF solution for 30 seconds. Trim the brain and slice at a thickness of 250-350 μm at a speed of 0.04-0.05 mm/s. Move the brain slices into a dish filled with carbon dioxide NMDG aCSF and keep it at 32-34°C for ≤12 minutes. Transfer the sections to a new dish of HEPES aCSF filled with carbon dioxide at room temperature [HEPES, which contains aCSF (mM): sodium chloride 92, potassium chloride 2.5, sodium dihydrogen phosphate 1.25, sodium bicarbonate 30, HEPES 20, Glucose 25, Thiourea 2, Sodium Ascorbate 5, Sodium Pyruvate 3, Calcium Chloride 2, Magnesium Sulfate 2]. After 1 hour, the slices were transferred to a recording dish containing a recording buffer [record aCSF (mM): sodium chloride 119, potassium chloride 2.5, sodium dihydrogen phosphate 1.25, sodium bicarbonate 24, glucose 12.5, chloride Calcium 2, magnesium sulfate 2]. The neuron-like mCherry positive cells were recorded under a microscope (Olympus BX51WI), and Clampex 10 was used to obtain the data.

6-OHDA PD mouse model

The study was based on previous studies ^4. Adult C57BL/6 mice were injected intraperitoneally (7-10 weeks). Inject 25mg/kg desipramine hydrochloride (D3900, Sigma-Aldrich) half an hour before anesthesia. After anesthesia, 3μg 6-OHDA (H116, Sigma-Aldrich) or normal saline was injected into the right medial forebrain tract of the mouse according to the following coordinates: anteroposterior (A/P) = -1.2mm, medial and lateral (M/L) = -1.1mm, dorsoventricular (D/V) = -5mm. One hour after the operation, all mice were injected subcutaneously with 1 ml of 4% glucose-saline solution. The mice consumed the soaked food pellets for the next 3 weeks.

Apomorphine-induced rotation test

Mice were intraperitoneally injected with 0.5 mg/kg apomorphine (A4393, Sigma-Aldrich) 10 minutes before the test. After that, each of them was placed in an opaque cylinder (30 cm in diameter) and recorded on it by a camera for 20 minutes. Rotation is defined as a whole body turning with one hind paw as the center and no head orientation is switched. Calculate the number of rotations on the injection side and the contralateral side. The data was quantified as the number of contralateral reversals within 20 minutes.

Cylinder test

Each mouse was gently put into a glass beaker (1000ml) and recorded with a camera for 10 minutes in front of it. Calculate the number of wall touches on the injection side and the contralateral paw respectively, and quantify the data as the ratio of the number of wall touches on the same side to the total number of wall touches.

Rotating rod test

All mice were trained for 2 days and tested on the third day. On the first day, the mice were trained 4 times on a rotating rod at a fixed speed of 4 laps/min, each for 300 seconds. On the 2nd and 3rd days, the mice were trained or tested 4 times at an acceleration of 4 to 40 laps/min. The time the mouse stayed on the rod before falling off was recorded as the stay period, and the average of the 3 longest stay periods was used for analysis.

Statistical analysis: set error bars by sem, and calculate statistical significance by unpaired two-tailed t test or one-way analysis of variance (p<0.05). All experiments were randomized to develop, not to use statistical methods to determine the pre-sample size, but our sample size reference ⁵ reported previously in the literature. It is assumed that the data distribution is normal but not formally tested. Data collection and analysis were not performed under blind experimental conditions.

Transient transfection of N2a cells, qPCR and RNA-seq

N2a cells were seeded in 6-well plates. According to standard procedures, Lipofectamine 3000 (Thermo Fisher Scientific) was used, and cells were transfected with 7 μg gRNA-CasRx-GFP vector. The control plasmid does not express gRNA. Two days after transfection, about 50,000 GFP-positive cells were collected from each sample by fluorescence activated cell sorting (FACS), and lysed for qPCR analysis. At the same time, the retina was separated to determine the expression of AAV. The RNA was extracted using Trizol (Ambion) and converted into cDNA using a reverse transcription kit (HiScript QRT SuperMix for qPCR, Vazyme, Biotech). Use AceQ qPCR SYBR Green Master Mix (Vazyme, Biotech) to track the amplification process.

Ptbp1 qPCR primer is: upstream primer, 5'-AGAGGAGGCTGCCAACACTA-3' (SEQ ID NO: 7);

Downstream primer, 5'-GTCCAGGGTCACTGGGTAGA-3' (SEQ ID NO: 8).

CasRx qPCR primer: upstream primer, 5'-CCCTGGTGTCCGGCTCTAA-3' (SEQ ID NO: 9);

Downstream primer, 5’-GGACTCGCCGAAGTACCTCT-3’ (SEQ ID NO: 10).

For RNA-seq, N2a cells were cultured in a 15-cm petri dish and transiently transfected with 70 μg plasmid. Collect ~500,000 GFP-positive (top 20% GFP) N2a cells by FACS, extract RNA, convert it into cDNA, and use it for full-transcriptome RNA-seq.

Intravitreal injection and subretinal injection

As mentioned earlier, NMDA and AAV (AAV-PHP.eB) were introduced by intravitreal and subretinal injections, respectively. ^{For subretinal injection, high titer (>1×10 13} ) AAV was injected into the eye using a Hamilton syringe (32G needle) under an Olympus microscope (Olympus, Tokyo, Japan). To determine reprogramming in the intact retina, a total of 1μl of GFAP-GFP-Cre (0.2μl) and GFAP-CasRx-Ptbp1 (0.8μl) were injected under the retina (Ai9 and C57BL/6 mice, 5 weeks old), Or GFAP-Cre-GFP (0.2μl) and GFAP-CasRx (0.8μl) are delivered to the retina. To determine the reprogramming in the damaged retina, dissolve NMDA to a concentration of 200 mM in PBS, and then inject 1.5 μl of NMDA solution into 4-8 week old Ai9 mice or 5-6 week old C57BL/6 mice by intravitreal injection. Mouse eyes (used for VEP and black and white scene preference testing). 2-3 weeks after NMDA injection, GFAP-GFP-Cre and GFAP-CasRx-Ptbp1 or GFAP-CasRx were co-delivered to the retina by subretinal injection. In order to evaluate the functional rescue of the damaged retina (VEP and light-dark box shuttle test), 5-6 weeks old mice (C57BL/6) were injected with NMDA to induce retinal damage, and GFAP-mCherry ( 0.2μl) and GFAP-CasRx-Ptbp1 (0.8μl) or GFAP-CasRx (0.8μl) mixture.

Immunofluorescence staining

One month after AAV injection, the eyes, optic nerve and brain were taken, fixed with 4% paraformaldehyde (PFA) for 2 hours (eyes and optic nerve) or 24 hours (brain), and then stored in 30% sucrose solution 2 (eyes) And optic nerve) or 24 (brain) hours. After embedding and freezing, the eyes and brain were sliced at a thickness of 30 μm. Primary antibodies for immunofluorescence staining: mouse anti-Brn3a (1:100, MAB1585, Millipore), rabbit anti-RBPMS (1:500, 15187-1-AP, Proteintech), rabbit anti-Sox9 (1:500, AB5535, Millipore), rabbit anti-Pax6 (1:500, 901301, Biolegent), rabbit anti-Prox1 (1:500, AB5475, Millipore), and secondary antibody: Cy ^TM 5 AffiniPure Donkey mouse anti-IgG (H+L) (1: 500,715-175-150, Jackson ImmunoResearch), Cy™ 5 AffiniPure Donkey rabbit anti-IgG (H+L) (1: 500, 711-175-152, Jackson ImmunoResearch). After applying the antibody, wash and mount the film. Use Olympus FV3000 microscope for imaging.

Electrophysiology

The mice were dark-adapted overnight before euthanasia. Under an infrared microscope at room temperature, the retina was dissected in an oxygenated (95% O2 / 5% CO2) artificial cerebrospinal fluid (ACSF) containing 126mM NaCl, 2.5mM KCl, 1.25mM NaH2PO4, 2mM CaCl2, 2mM NaHCO3 and 10mM glucose. Place the RGC of the retina facing the cell recording groove on the table of the upright microscope. A two-photon (λ=1030nm) microscope was used to identify the tdTomato-positive cells in the ganglion cell layer and record them under infrared light. ASCF and 0.25mM Alexa488 hydration were added to the pipette (4-7MΩ) used for recording. Use Multiclamp 700A amplifier and pClamp10 software package (Molecular Devices) for recording. The signal is low-pass filtered at 1kHz and digitized at 10kHz. The white LED light is used to deliver the full-field light stimulation. After recording, inject current pulses to fill the cells to visualize their morphology.

Visual evoked potential

A mixture of fentanyl (0.05mg/kg), midazolam (5mg/kg) and medetomidine (0.5mg/kg) was injected intraperitoneally in mice. The head of the mouse was fixed in a stereotaxic instrument, and the body temperature was maintained at 37°C through a heating blanket. A craniotomy (approximately 1mm in diameter) was performed on both sides of the main visual cortex (V1) (AP-3.6 to -3.9mm, ML 2.2mm), and the dura mater was removed. The visual stimulus is emitted by a 17-inch LCD display (Dell P170S, maximum brightness 69cd/m2), which is 8 cm away from the eyes at the recording end, and at the same time shields the side of the eye on the same side of the recording end from visual stimulation. We performed 100 repetitive flash stimuli for 2 seconds (full field of view, 100% contrast) with an interval of 2 seconds. Use a multi-point silicon probe (A1×16-5mm-50-177, NeuroNexus Technologies) to record at V1 (AP-3.6 to -3.9mm, ML 2.2mm), and the cortical depth reached by the electrode tip of each recording is about 900μm. Both the reference wire and the ground wire are placed in a small craniotomy at least 3 mm away from the recording point. The Cerebus 32-channel system (Blackrock microsystems) was used to amplify and filter neural responses. Use broadband front-end filter (0.3～500Hz) to sample the local field potential (LFP) signal at 2kHz or 10kHz. LFP response to stimulation is used to flash the full screen current source density (CSD) analysis to determine the location of the cortical layer ^43. In order to generate the CSD distribution profile, we calculated the second-order spatial derivative of LFP with the following equation:

among them

Is LFP, z is the coordinate of the recording end, Δz is the distance between adjacent recording ends, and nΔz is the differentiation grid (n=2). Layer 4 (granular layer) is defined as those recorded positions at the initial current receiver. We used the layer 4 channel showing the maximum average amplitude to analyze the visual evoked response of each mouse.

Black and white box preference test

The equipment used for the light-dark box shuttle experiment includes a box with a door, which is divided into a small (one-third) dark box part and a large (two-thirds) lighting part (550 lumens). The mouse can move freely between the two compartments for 10 minutes. The time the mice spend in each compartment is recorded by the camera and then analyzed using Ethovision XT. After each test, clean the compartment with 70% ethanol to avoid olfactory cues.

Statistical Analysis

All values are shown as mean ±s.e.m. Unpaired t-test was used to determine statistical significance (p<0.05). All experiments were randomized and no statistical method was used to estimate the sample size, but our sample size was similar to that reported in previous publications. It is assumed that the data distribution is normal but not formally tested.

Example 1 Using CasRx to specifically knock down Ptbp1 in vitro

In order to determine the efficiency of CasRx-mediated knockdown of Ptbp1, six gRNAs targeting Ptbp1 were first designed, and their inhibitory efficiency was compared in cultured N2a cells and astrocytes (Figure 1A and 1B) . It was found that the co-transfection of two gRNAs (5 and 6 combinations) targeting Ptbp1 exon IV and VII regions can achieve 87%±0.4% and 76%±4% in N2a cells and astrocytes, respectively. Decrease (Figures 1C and 1D). The RNA whole transcriptome sequencing data further showed that this knockdown is very specific (Figures 1E, 1F and 2A).

Example 2 Conversion of Muller glial cells into optic ganglion cells in mature retina

Previous studies have found that knockdown of Ptbp1 by shRNA can transform cultured mouse fibroblasts and N2a cells into functional neurons. Next, we will investigate whether Ptbp1 knockdown in the mature retina will convert Mueller glial cells in vivo Transform into optic ganglion cells. In order to specifically and permanently label retinal Mueller glial cells, we injected AAV-GFAP-GFP-Cre into the eyes of Ai9 mice (Rosa-CAG-LSL-tdTomato-WPRE) to specifically induce tdTomato in Mueller glial cells. Expression in cells (Figures 2B and 2C). We also constructed AAV-GFAP-CasRx-Ptbp1 (gRNA 5+6) driven by the Mueller glial cell-specific promoter GFAP, hoping to specifically knock down Ptbp1 in Mueller glial cells and we also constructed The control virus AAV-GFAP-CasRx, which does not target Ptbp1 (Figures 3A and 2D). We first co-injected AAV-GFAP-CasRx-Ptbp1 and AAV-GFAP-Cre-GFP into the retina of Ai9 mice aged about 5 weeks. After 1 month, we found that many tdTomato-positive cells were specific to optic ganglion cells. The antibodies Brn3a or Rbpms were co-labeled in the retinal ganglion cell layer (GCL), but we did not find such cells in the retina injected with the control AAV vector (Figure 3B-3E). These results indicate that knocking down Ptbp1 in the mature retina can convert Muller glial cells into optic ganglion cells. It is worth noting that since the transformed optic ganglion cells are no longer Mullerian cells, the expression of GFP driven by GFAP is also reduced in the induced optic ganglion cells (Figure 2E). We also proved this existence through other methods (Figure 4). In addition to optic ganglion cells, we also found amacrine nerve cells (Figure 5).

Example 3 Conversion of MG to RGC in a mouse model of retinal injury

In order to explore whether MG-induced RGC can replace the lost RGC in a mouse model of retinal injury, we injected NMDA (200mM) into the vitreous of (NMDA, 200mM) Ai9 mice aged 4 to 8 weeks, which caused most The death of RGC and the decrease in the thickness of the inner plexiform layer (IPL). Two to three weeks after NMDA injection, AAV-GFAP-CasRx-Ptbp1 plus AAV-GFAP-GFP-Cre or control AAV virus was injected into the eyes (Figures 6A and 6B). One month after AAV injection, we found that the number of Brn3a or Rbpms positive cells in the optic ganglion cell layer increased significantly in the retina injected with AAV-GFAP-CasRx-Ptbp1. It is interesting that most of these cells are positive for tdTomato. We found no increase in the optic ganglion cell layer injected with control AAV (Figure 6C-6F). In order to determine whether MG-induced RGC is integrated into the retinal loop and has the ability to receive visual information, we performed extracellular recording of MG-induced RGC under a two-photon microscope to monitor the response induced by light stimulation (Figure 6G). We found that among the 8 cells examined, 6 cells showed action potentials induced by light stimulation (Figure 6H). Among these cells, five are ON cells and one is OFF cells (Figure 6H). These results indicate that functional RGCs can transform MG by reducing the expression of Ptbp1 in Muller cells in the damaged retina.

Example 4 Induced optic ganglion cells partially restore visual function

In the visual system, visual information is projected to the dorsolateral geniculate nucleus and superior colliculus of the brain through RGC (Figure 8A). In the permanently damaged retina, we observed a large number of tdTomato-positive axons in the retina and optic nerve through treatment, but no such axons were seen in the control group (Figures 8B and 8C). It is worth noting that we also found a large number of tdTomato positive axons in the dorsal geniculate nucleus and superior colliculus, and the distribution on the contralateral side of the brain is much richer than the ipsilateral side (Figure 8D and 8E). Corresponding to the correct projection of RGC in normal mice. In order to study whether impaired visual function can be improved by induced RGC. One month after injection of AAV virus, we recorded visual evoked potentials (VEP) in the primary visual cortex (V1) of anesthetized mice (Figure 8F). In mice with retinal injury treated with AAV-GFPA-CasRx-Ptbp1 and AAV-GFAP-mCherry, we found very obvious evoked potentials, and the amplitude was similar to that found in uninjured mice. In the control group, we only observed a very weak response (Figure 8G and 8H). These results support that the induced optic nerve cells probably established synaptic connections with the existing functional dorsal geniculate nucleus neurons in the brain, thereby partially restoring the transmission of visual information to the primary visual cortex. From a behavioral perspective, we explored whether CasRx-mediated conversion of MG to RGC can restore the visual behavior lost due to retinal damage (Figure 8I). First we injected NMDA into the eyes of the mice, and then injected the AAV virus. In the light/dark preference test, untreated mice have no obvious tendency to stay in a dark room, which is consistent with vision loss caused by retinal damage. In contrast, the duration of the treated mice in the dark room increased significantly, even close to the level of healthy control mice (Figure 8J), suggesting that the induced optic nerve cells improved the visual behavior of mice with visual impairment.

Example 5 The projection process of optic ganglion cells to the brain

In order to explore at what time points can start to see the optic ganglion cells induced by Mueller glial cells, we set five different time points (1 week, 1.5 weeks, 2 weeks, 3 weeks, and 1 month). We found that at 1.5 weeks after AAV injection, tdTomato+Rbpms+ and tdTomato+Brn3a+ cells were first found in the retina, and the number of these cells gradually increased over time (Figures 7A and 7B). Our results also indicate that 1.5 weeks after AAV injection, there is an intermediate stage in which the induced RGC migrates from INL to the optic nerve cell layer (Figure 7C). These findings were also confirmed in NMDA-induced permanent damage to the retina (Figure 7D). Regarding when to project to the correct brain area, we first found that the tdTomato-positive axons in the optic nerve increased significantly over time (Figure 9A). In the brain, we did not find any projections in the brain at 1 week, and at 1.5 weeks after AAV injection, we started to find tdTomato-positive axons in the contralateral dorsal geniculate nucleus. This projection did not appear. On the same side (Figure 9B). When AAV was injected for 2 weeks, we started to find that it induced the projection of optic ganglion cells in the contralateral inferior colliculus (Figure 5C). When AAV was injected for 3 weeks, we had both the contralateral and ipsilateral dorsal geniculate nucleus and superior colliculus. The induced projection of optic ganglion cells was found, and the density of this projection further increased at 1 month (Figure 9B-9D). We also observed similar results in the damaged retina injected with NMDA (Figure 10A-10C).

Example 6 Transformation of astrocytes into neurons

In order to further explore the potential use of CasRx-induced glial-neuron transformation in other systems, we further investigated whether knocking down the expression of Ptbp1 in astrocytes in the striatum can transform astrocytes locally Dopamine neurons, a cell type closely related to the occurrence of Parkinson's disease (PD). We first injected AAV-GFAP-mCherry into the striatum of wild-type mice to label astrocytes, and at the same time co-injected AAV-GFAP-CasRx-Ptbp1 (gRNA: 5+6) to downregulate astrocytes Expression of Ptbp1 in glial cells (Figures 11A and 11B). As a control, we used AAV-GFAP-CasRx that does not contain Ptbp1 gRNA. We found that both mCherry and CasRx are expressed in large amounts in astrocytes and show a high co-infection efficiency in the striatum. Among them, 99%±1% of mCherry+ cells express CasRx (82%±2% of GFAP ⁺ cells express mCherry, while 95%±1% of mCherry+ cells express GFAP) (Figures 11C and 11D). One week after AAV was injected into the striatum, we found that the expression of Ptbp1 in astrocytes was down-regulated (Figures 11E and 11F). One month after AAV virus injection, we found that a high proportion of mCherry+ cells expressed the mature neuron marker NeuN (48%±10%, SEM, n=6 mice), but injected with AAV-GFAP-mCherry and AAV-GFAP -No such expression was found in the control striae group of CasRx (0.97%±0.45%, SEM, n=6) (Figure 11G and 11H). To further explore the specific types of these transformed neurons, we performed immunostaining using antibodies against specific neurons. We found that about 50% of induced neurons expressed glutaminase (Figure 11I and 11J), which is a marker of excitatory glutamatergic neurons, and we also found a small number of induced neurons One interneuron subtype marker SST was expressed, and no cells expressed another interneuron subtype marker PV (Figures 11K and 11L). We also used the co-staining of dopamine neuron marker tyrosine hydroxylase (TH) and NeuN to determine whether there are dopamine neurons in the transformed neurons. We found that some (7.5%±3%, SEM) mCherry+ cells expressed TH (Figure 11M-11O). In addition, we found that the expression of mCherry in the transformed neurons continued to be expressed at least 1 month after infection (Figure 11G), which is consistent with previous reports.

Example 7 Induction of Dopamine Neurons

In order to explore the potential clinical application of CasRx-mediated neuronal transformation in the striatum, we induced a Parkinsonian mouse model by unilaterally infusing 6-hydroxydopamine (6-OHDA) into the substantia nigra. This infusion can cause the death of dopamine neurons in the substantia nigra and the degeneration of dopaminergic projections in the ipsilateral striatum (Figure 13A-13C). Three weeks after 6-OHDA injection, AAV-GFAP-CasRx-Ptbp1 (or AAV-GFAP-CasRx as a control) and AAV-GFAP-mCherry were injected into the striatum on the same side. At the same time, the transformation of striatal cells was analyzed at different time points (Figure 12A and 12B). One month after the virus injection, we found that a high percentage of mCherry cells expressing dopamine neurons in the striatum of mice injected with AAV-GFAP-CasRx-Ptbp1 and AAV-GFAP-mCherry in 6-OHDA-induced injury The marker TH, and the percentage will increase when AAV is injected for 3 months (19%±0.4%, SEM, n=5 mice, one month; 32%±7%, SEM, n=3 Mouse, at 3 months) (Figure 12C, 12D, 13D and 13E). In the control group, such cells were rarely observed (Figure 12C, 12D and 13D-13F). In addition, about 80% of the TH ⁺ cells in the virus injection area were mCherry+ (Figures 12E and 13G), indicating that these dopamine cells were mainly transformed from astrocytes. We noticed that the percentage of mCherry+TH+ cells in wild-type (without 6-OHDA damage) mice was lower than that in 6-OHDA-damaged mice (Figure 13H), indicating that the repair mechanism after injury may promote TH+ neurons Of induction. We also found that induced dopamine neurons express mature dopamine neuron marker dopamine transporter Slc6a3 (DAT), which does not exist in striatal neurons that transiently express TH. We found that a high proportion of mCherry positive cells expressed DAT (10%±3%, SEM, n=5, 1 month; in the striatum injected with AAV-GFAP-CasRx-Ptbp1, 31 mCherry+DAT+ cells %±7%, at 3 months, n=3 mice), and almost no such cells were found in the striatum injected with the control virus (Figure 12C, 12F, 13D and 13I). The co-immunostaining of TH and DAT further showed that most mCherry+TH+ cells express DAT (Figure 12C, 12G and 13D), indicating that most induced dopamine neurons express mature dopaminergic markers. In addition, mCherry+ cells also expressed two other midbrain dopamine neuron markers, namely dopa decarboxylase (DDC) and forkhead box protein A2 (FOXA2) (Figure 13J-13M), further verifying the transformed neurons Dopaminergic neurons. Previous studies have pointed out that 6-OHDA injury will transiently induce the expression of TH in some interneurons in the mouse striatum. Here, we evaluated this. Three months after AAV injection, we co-stained the interneuron markers PV+, SST+ and calretinin+ (CR+). We found that none of these interneuron markers were co-localized with mCherry+TH+ cells, indicating that the transformed TH+ neurons were not transiently induced TH+ neurons (Figure 13N). In order to explore the subtypes of induced dopamine neurons, we used two substantia nigra A9 region-specific dopamine neuron markers ALDH1A1 and GIRK2 to co-stain TH, and ventral tegmental area (VTA) dopamine neuron-specific marker calcium Binding protein (Calbindin) was co-stained with DAT. Our results show that almost all induced neurons express ALDH1A1 and GIRK2, but do not express calbindin (Figure 12H-12J), suggesting that induced dopamine neurons are very similar to dopamine neurons in the substantia nigra. Next, we did a whole-cell recording of electrophysiology on brain slices. We found that most neuron-like mCherry positive cells (20 out of 22 cells) can respond to action potentials induced by depolarizing currents in current clamp mode (Figure 12K). We also observed the spontaneous postsynaptic current (Vc=-70mV) in voltage clamp mode, indicating that the transformed neurons can receive functional synaptic input (Figure 12L and 12M). In addition, in 4 of the 10 neurons examined, we observed delayed voltage rectification induced by hyperpolarization activation current (Ih) (Figure 12K), which is also one of the hallmarks of midbrain dopamine neurons. Next, in order to determine whether the induced dopamine neurons can release dopamine, we performed immunostaining and found that most of the induced dopamine cells expressed vesicle monoamine transporter 2 (VMAT2) (Figure 12N), which is a modulator of dopamine The packaging, storage and release of protein. We also found that many cells in the striatum that were injected with the virus have absorbed fluorescent dopamine derivatives (FFN206), which is a VMAT2 substrate that can determine whether the expressed VMAT2 is functional. Under the high potassium chloride treatment, we found that the fluorescent part was reduced, indicating that the transformed cells have a dopamine releasing function (Figure 12O-12Q). Our results show that CasRx-mediated Ptbp1 knockdown can effectively induce dopaminergic neurons in the striatum of PD model mice.

Example 8 Improvement of motor function of Parkinson's disease model mice

We further examined whether the dopamine neurons induced in the striatum can alleviate the motor symptoms in a mouse model of 6-OHDA-induced Parkinson's disease (Figure 14A). We also evaluated motor function with and without drug induction. For drug-induced activities, we first studied the contralateral rotation behavior induced by apomorphine, which is widely used to test behavioral changes caused by unilateral dopamine neuron loss. We found that compared with control mice (AAV-GFAP-CasRx and AAV-GFAP-mCherry or injected with saline), Ptbp1 knockdown mice (injected with AAV-GFAP-CasRx-Ptbp1 and AAV-GFAP-mCherry) The net number of spins induced by pomorphine (counted as the number of contralateral shear ipsilateral spins) was significantly reduced, and its level was comparable to that of uninjured healthy mice (Figure 14B, 13O and 13P). In another test of ipsilateral rotation behavior caused by systemic amphetamine administration, the intercellular dopamine concentration was increased by inhibiting the uptake of dopamine by DAT in the striatum. Compared with control mice, mice injected with AAV-GFAP-CasRx-Ptbp1 had significantly lower net spins (calculated as contralateral spins on the same side) and ipsilateral spin ratio (calculated on ipsilateral/total spins) (Figures 14C, 14D and 13Q). These results indicate that neurons induced in the striatum can release enough dopamine to alleviate the motor dysfunction in PD model mice caused by the drug. In addition, we tested whether the two kinds of drug-free motor functions were improved, namely the asymmetry of forelimb use and motor coordination. We found that compared with control mice, mice injected with AAV-GFAP-CasRx-Ptbp1 had a significant reduction in the cylinder ipsilateral touch percentage and a longer duration on the rotating tripod (Figure 14E and 14F ). Taken together, these results indicate that Ptbp1 knockdown of astrocytes in the striatum mediated dopamine neuron transconversion reduces motor dysfunction in Parkinson's disease model mice.

discuss

In this work, our research shows that glial cells can be effectively transformed into neurons through CasRx-mediated down-regulation of Ptbp1. In the NMDA-induced retinal injury model, Ptbp1 knockdown can induce the conversion of MG in the injured retina to RGC, which partially restores the visual response and vision-dependent behavior. In a mouse model of Parkinson's disease induced by 6-OHDA, it can induce astrocytes in the striatum into dopamine neurons and reduce motor dysfunction related to the loss of substantia nigra dopamine neurons. These results indicate that down-regulating the expression of a single RNA-binding protein Ptbp1 is sufficient to convert glial cells into specific types of neurons that are lost in different nervous systems, which provides a new method for future therapeutic applications. Short hairpin RNA (shRNA) technology can cut or suppress the desired transcript, but it has a very serious off-target effect. Cas13-mediated knockdown is not only more efficient than RNAi, but can also reduce off-target effects to a large extent, which has greater potential in therapeutic applications. In addition, CasRx is the smallest one in the Cas13 protein family and can be packaged in an AAV with the CRISPR array (encoding multiple guide RNAs). In the field of gene editing, the RNA-targeted CRISPR system CasRx can avoid the risk of permanent DNA changes caused by the DNA-targeted CRISPR-Cas9 editing system, making it safer in clinical applications.

references:

1.Mccarthy,K.D.&Devellis,J.Preparation Of Separate Astroglial And Oligodendroglial Cell-Cultures From Rat Cerebral Tissue.Journal Of Cell Biology 85,890-902 (1980).

2. Zhou, H.et al. Cerebellar modules operate at different frequencies. Elife 3, e02536 (2014).

3. Xu, H.T.et al. Distinct lineage-dependent structural and functional organization of the hippocampus.Cell 157, 1552-1564 (2014).

4.Su, J.et al. Reduction of HIP2 expression causes motor function impairment and increased vulnerability to dopaminergic degeneration in Parkinson's disease models.Cell Death Dis 9,1020 (2018).

5.Chavez, A.et al. Comparison of Cas9 activators in multiple species. Nat Methods 13,563-567 (2016).

All documents mentioned in the present invention are cited as references in this application, as if each document was individually cited as a reference. In addition, it should be understood that after reading the above teaching content of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the appended claims of the present application.

Claims

Use of an inhibitor of Ptbp1 gene or RNA or its coded protein, characterized in that it is used to prepare a composition or preparation, and the composition or preparation is used to prevent and/or treat the nervous system related to functional neuron death disease.
The use according to claim 1, wherein the composition or preparation is further used for one or more uses selected from the following group:

(a1) Inducing astrocytes to transdifferentiate into dopamine neurons;

(b1) Treatment of dyskinesia in mammalian Parkinson's disease;

(c1) Inducing the transformation or differentiation of glial cells into functional neurons;

(d1) Treatment of neurological diseases related to optic ganglion cell (RGC) degeneration;

(e1) Prevention or treatment of retinal diseases;

(f1) Prevention and/or treatment of neurodegenerative diseases;

(g1) Transdifferentiation of Muller glial cells into optic ganglion cells;

(h1) Treatment of visual impairment caused by the death of mammalian optic ganglia.
The use according to claim 2, wherein the astrocytes are derived from the striatum, substantia nigra, spinal cord, dorsal midbrain or cerebral cortex, preferably, the astrocyte The cells are derived from the striatum.
The use according to claim 1, wherein the functional neurons are selected from the group consisting of RGC neurons, dopamine neurons, or a combination thereof.
The use according to claim 1, wherein the inhibitor is selected from the group consisting of antibodies, small molecule compounds, microRNA, siRNA, shRNA, antisense oligonucleotides, nucleic acid aptamers, gene editors, Or a combination.
A composition characterized by comprising:

(a) A gene editing protein or an expression vector thereof, the gene editing protein is selected from the group consisting of CasRx, CRISPR/Cas9, Cpf1, Cas9, Cas13a, Cas13b, Cas13c, RNA targeted gene editing protein, or a combination thereof; and

(b) gRNA or its expression vector, said gRNA is DNA or RNA that guides the gene editing protein to specifically bind to the Ptbp1 gene.
A medicine box is characterized in that it comprises:

(a1) The first container, and the gene editing protein or its expression vector located in the first container, or a drug containing the gene editing protein or its expression vector, the gene editing protein is selected from the following group: CasRx, CRISPR/ Cas9, Cpf1, Cas9, Cas13a, Cas13b, Cas13c, RNA targeted gene editing protein, or a combination thereof;

(b1) The second container, and the gRNA or its expression vector, or a drug containing the gRNA or its expression vector, in the second container, the gRNA is DNA or RNA that guides the gene editing protein to specifically bind to the Ptbp1 gene.
A use of the composition according to claim 6 or the kit according to claim 7, characterized in that it is used to prepare a medicine for the prevention and/or treatment of neurological diseases related to functional neuron death.
A method for promoting the differentiation of glial cells into functional neurons, which is characterized in that it comprises the following steps:

Glial cells are cultured in the presence of Ptbp1 gene or RNA or an inhibitor of its encoded protein or the composition of claim 6, thereby promoting the differentiation of glial cells into functional neurons.
A method for screening candidate compounds for the prevention and/or treatment of neurological diseases related to functional neuron death, characterized in that the method comprises the steps:

(a) In the test group, add the test compound to the cell culture system, and observe the expression (E1) and/or activity (A1) of Ptbp1 in the cells of the test group; in the control group, in the same cell Add a test compound that does not target Ptbp1 to the culture system, and observe the expression (E0) and/or activity (A0) of Ptbp1 in the cells of the control group;

Wherein, if the expression level (E1) and/or activity (A1) of cells in the test group is significantly lower than that of the control group, it indicates that the test compound is a preventive and/or inhibitory effect on the expression and/or activity of Ptbp1 Candidate compounds for the treatment of neurological diseases related to functional neuronal death.